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ABSTRACT 
Drug-induced liver injury (DILI) is a major human health concern, estimated to account 
for about half of all cases of acute liver failure in the general population. DILI also 
represents a significant problem in drug discovery, being one of the most common 
reasons for regulatory actions, including boxed warnings, restricted marketing and 
withdrawals of marketed drugs. Adverse drug effects in the liver are hard to detect at an 
early stage during drug development, much owing to the shortcomings of the currently 
available pre-clinical model systems. The work presented in this thesis aimed to refine 
and further develop more sensitive, human in vitro models and methods for better 
prediction of DILI and the underlying mechanisms. 
 
Mono-culture of human primary hepatocytes is the closest in vitro model to the human 
liver, currently considered the golden standard in drug development. However, 
limitations, such as low availability of qualitative liver tissue and phenotypical instability 
of these cells in culture, require new sources of functional human hepatic cells. In this 
thesis, we have shown that high-density culture of the human hepatoma cell line Huh7 
induces a spontaneous, hepatic differentiation process, without the need for inducers as is 
usually the case. A particular increase of CYP3A4 gene- and protein expression and 
catalytically activity was observed. Moreover, we found that the large increase in 
CYP3A4 expression seen in the confluent Huh7 cells is mediated by PXR nuclear 
translocation and increased PXR mediated transcriptional activity, most likely as a result 
of decreased CDK2 activity and cell cycle arrest. The high constitutive expression of 
CYP3A4 in the confluent Huh7 cells makes this cell system useful for studies of 
mechanisms for regulation of PXR and the CYP3A4 gene. 
 
The unique characteristics of stem cells make them an attractive large-scale source of 
hepatic cells for drug development and safety assessment. Using a novel stepwise 
differentiation protocol we have been able to differentiate human embryonic stem cells 
(hESC), via definitive endoderm and progenitor stages to hepatocyte-like cells which 
exhibit many hepatocyte-specific features and functions, including CYP metabolic 
activities. A dynamic three-dimensional (3D) bioreactor system was shown to prolong 
and maintain the specific functions of primary hepatocytes, as well as facilitate the hepatic 
maturation of hESC into hepatocyte-like cells. 
 
It has become increasingly evident that inflammatory event plays a significant role in 
many DILI events. Thus, in vitro systems containing a population of immune competent 
cells in combination with hepatic cells could be of great significance for studying 
mechanisms underlying DILI. A co-culture cell model consisting of hepatocytes and 
monocytes has been developed where the cells were separated by a semipermeable 
membrane. The hepatotoxic drug troglitazone caused a potentiated and more rapid 
cytotoxic effect in cells treated in the co-culture compared to the single cultures. 
Troglitazone treatment also resulted in an increased expression of several stress-related 
genes in the co-cultures compared to the single cultures. These results suggest a 
synergistic cytotoxic effect by soluble mediators released by the cells and underscores the 
importance of incorporating several different hepatic cell types in order to generate more 
sensitive in vitro systems and better prediction of DILI. 
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1 INTRODUCTION 
Thanks to extensive research, new and improved drugs are constantly being developed 
with the intention to prevent, treat and cure diseases. Several important discoveries in 
pharmacology, such as the antibiotics, have improved our physical and mental 
wellbeing and have markedly increased the average life expectancy of humans (about 
70%) during the last century [1]. When properly used, medical drugs are generally safe 
and effective for most patients, however, adverse drug reactions (ADRs) do occur and 
may be lethal for the patient. During the later years the number of reported ADRs in 
patients has increased drastically, uncorrelated with the prescription level of drugs [2]. 
A Swedish study showed that ADRs are responsible for more than 10% of all hospital 
admissions [3]. Moreover, ADRs cause about 3% of all deaths in the general 
population which makes it the seventh most common cause of death in Sweden [4]. 
Similar numbers has been presented for other European countries [5, 6], as well as for 
USA [7]. Apart from individual suffering, ADRs constitute a considerable economic 
burden for the community, valued to cost almost as much the drug treatment itself [3, 
8].  
 
In recent years the pharmaceutical industry has been struggling with low rate of new 
drug candidates, long discovery processes and increasing developmental costs. 
Discovery and marketing of a new drug typically takes 10-15 years and costs around 
900 million USD [1]. Thus, ADRs also have a major economic impact on the 
pharmaceutical industry, resulting in unsatisfactory marketing approval rates, post-
marketing restrictions, boxed warnings and withdrawals of marketed drugs [9, 10]. Due 
to insufficient pre-clinical methods the industry also fights with high failure rates 
during later stages of drug development, many of them caused by toxicology and 
clinical safety issues [1]. The failure rates in phase III clinical trials are estimated to 
exceed 40% with hundreds of million dollars lost for the drug companies [11].  
 
One of the most commonly reported idiosyncratic drug reactions are liver related 
injuries [12, 13]. Idiosyncratic drug reactions are hard to detect during pre-clinical 
studies since the toxic reactions are unpredictable based on what is known about the 
pharmacological properties of the drug. Moreover, idiosyncratic drug reactions often 
occur after some period of latency [13]. Drug induced liver injuries (DILI) are serious 
events which may cause acute liver failure, leading to liver transplantation or even 
death of the patient. In order to decrease the above mentioned problems there is an 
urgent need to improve the biological significance of the pre-clinical models. To date, 
the principle source of information regarding possible liver related ADRs is based on 
laboratory animal testing (in vivo methods) in combination with various cell culture 
models (in vitro models). Due to inter-species differences, in vivo studies have low 
predictive value for drug related toxic effect in humans. In addition, the use of animals 
raises major ethical and societal concern [14, 15]. According to existing animal 
protection EU legislation (Directive 86/609/EEC), pharmaceutical companies are 
obliged to apply available methods to replace, reduce and refine (“The 3R’s”, Russel 
and Burch, 1959) the use of animals in both safety and efficacy evaluations. Thus, 
innovated, sensitive and reliable humanized in vitro models that better mimics the in 
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vivo situation in the liver are essential for an effective and accurate preclinical 
evaluation of new chemical entities and have been addressed in the thesis presented 
here. 
 
 
1.1 THE HUMAN LIVER 
1.1.1 Embryonic liver development 
Life begins with the fertilized egg (zygote), the combined, haploid set of chromosomes 
from two different individuals (Figure 1). The dividing zygote grows into a blastocyst 
with a flattened cavity called the epiblast. By a morphogenetic process named 
gastrulation some cells from the epiblast are rearranged by an inward movement, 
through a structure called the primitive streak, and the three germ layers are formed; 
ectoderm, endoderm and mesoderm, which gives rise to the different organs and tissues 
in the body [16]. The liver is developed from the endoderm germ layer which is 
suggested to arise from the mesendoderm, a common precursor cell population to the 
mesoderm [17]. The TGFβ/Activin/Nodal signaling factor group, belonging to the 
transforming growth factor beta (TGFβ) superfamily, together with Wnt signaling has 
shown to be particular important for initiation of gastrulation and definitive endoderm 
formation [16, 18, 19]. Within the endodermal linage high Nodal signaling activates 
different nuclear transcription factors, such as FOXA2 (forkhead box protein, also 
called HNF-3β), SOX17 (SRY (sex determining region Y)-box 17) and GATA4 [20-
22]. These transcription factors, in turn, activates and regulates the transformation of 
the definitive endoderm into a two dimensional sheet of cells, ultimately forming the 
primitive gut tube [17, 23, 24]. The gut tube becomes regionalized and the hepatic 
progenitor cells of the ventral foregut endoderm are stimulated to form the liver bud. 
This process is stimulated by the interaction with the surrounding mesoderm tissues 
[25] secreting fibroblast growth factors (FGFs) and bone morphogenetic proteins 
(BMPs) [20, 26, 27]. The specialized hepatic progenitor cells in the growing liver bud 
are called hepatoblasts and express liver specific markers, such as alpha-fetoprotein 
(AFP), albumin (ALB) and fetal forms of cytochrome P450s (CYPs), as well as biliary 
epithelium markers like cytokeratin19 (CK19) [28]. Thus, the hepatoblasts has shown 
to be bipotential, capable of differentiating into both hepatocytes and cholangiocytes 
[29]. The organogenesis is regulated by the interplay and flucturation of different 
growth factor released from surrounding tissues [20, 30] but also by infiltrating 
hematopoietic cells that influence liver maturation by secretion of cytokines, like 
Oncostatin M (OSM) and tumor necrosis factor α (TNFα) [31, 32]. The transcription 
factor HNF4α (hepatocyte nuclear factor 4α) is not only a vital player for early 
embryonic development and hepatocyte maturation, but also for metabolic regulation 
and proper liver function in the adult liver [33]. The fetal liver differs from the adult 
liver regarding specific functions such as CYP activities, exhibiting a change in 
metabolic profile after birth to be able to cope with the exposure to endotoxins and 
xenobiotics [34].  
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Figure 1. Schematic illustration of embryonic liver development compared to hepatic differentiation of 
human embryonic stem cells (hESC). Genes expressed at different developmental/differentiation stages 
are shown in pink. Selected soluble factors, typically added during hepatic differentiation of hESC, are 
also shown. Illustrations adapted from [35] with permission from Terese Winslow. OCT4, Octamer-
binding transcription factor; SOX2, SRY (sex determining region Y)-box 2; A1AT, Αlpha-1antitrypsin. 
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1.1.2 Liver structure and functions  
The liver is the largest internal organ in the body and performs several essential 
functions. These include bile production, plasma protein synthesis, glucose homeostasis 
and glycogen storage, processing and storage of fats, such as cholesterol, and 
production of hormones [36]. The liver is a highly specialized tissue that comprises 
many different cell types, further described below. From a histologically perspective 
the liver consists of small functional units called hepatic lobules. The liver is supplied 
with oxygenated blood from the hepatic artery and venous blood from the portal vein 
entering the periportal area of the lobule and via branches of small interlobular vessels. 
The mixed blood flows through vascular channels called sinusoids and leaves the 
lobule via the hepatic central vein located in the center of the lobule. Bile is secreted by 
the hepatocytes into bile canaliculi, flows in the opposite direction of the blood and 
empties into the bile ducts that are lined by epithelial cells called cholangiocytes. The 
bile is ultimately secreted into the duodenum where it facilitates the digestion of lipids 
[36]. The lobule is divided in zones based on functionality. The concentration of 
oxygen, nutrients, insulin and glucagon is highest in the periportal area and decreases 
towards the central vein. As a result of the concentration gradient, hepatocytes in the 
different zones have different morphology and function [37]. For example, hepatocytes 
around the central vein have higher density of endoplasmic reticulum and possess the 
highest levels of enzymes involved in detoxification and bioinformation [38, 39]. 
Substances from orally consumed food and drugs reach the liver via the venous blood 
from the intestine, which is filtered through the liver before entering the systemic blood 
circulation. This makes the liver a central organ in metabolism of both endogenous 
substances, such as bilirubin and ammonia, as well as exogenous substances, like 
bacterial toxins and alcohol [36]. Most pharmaceutical drugs available on the market 
today are administered orally which makes the liver a highly exposed organ for drug 
toxicity. Due to its central position in the body, the liver also functions as an important 
immune organ harboring many cells involved in both the innate and the adaptive 
immune response [40].  
 
1.1.3 Hepatic cell types  
The liver is comprised of several different cell types, all with unique and vital functions 
(Figure 2). The predominant cell type, the parenchymal cells, is the hepatocytes which 
constitute about 70% of all the hepatic cells. Of the non-parenchymal cells, the 
sinusoidal endothelial cells comprise the major part, followed by immune cells 
(Kupffer cells and lymphocytes), biliary cells (cholangiocytes) and stellate cells [40, 
41]. The liver also harbors small amounts of liver specific stem cells called oval cells 
[42].  
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Figure 2. The proportion of parenchymal (hepatocytes) and non-parenchymal cells in a healthy liver.  
Adapted from [41].  
 
 
1.1.3.1 Hepatocytes 
The hepatocytes are rich in cellular organelles such as mitochondria, endoplasmic 
reticulum and Golgi apparatus, a sign of active protein synthesis and secretion from 
these cells [43]. Hepatocytes have a large nucleus and about 25% of the cells are bi-
nucleated which often results in polyploidy, suggested to be an important mechanism 
to restrict liver growth and prolong cell survival [44]. The hepatocellular membranes 
have a complex structure with different membrane sections with different biochemical 
composition and functional properties: the basolateral section (facing the sinusoids), the 
lateral (inter-cellular) section, and the apical section facing the bile canaliculi [36].  
 
The hepatocytes possess a variety of different functions. They produce bile that is vital 
for the digestion of lipids. Many serum proteins i.e. albumin and blood clotting factors 
are synthesized by the hepatocytes and they also regulate the glucose homeostasis in 
the blood in response to glucagon and insulin signaling. The hepatocytes are also 
essential for the biotransformation of many endogenous substances, like different 
serum proteins, lipids and steroids. They also metabolize many exogenous substances, 
such as alcohol, chemicals and pharmaceuticals. Hepatocytes also play an important 
role in the hepatic immune response via the production of complement factors and 
acute phase proteins as a response to cytokine stimuli, like IL-6 (interleukin-6), IL-1β 
and TNFα, produced by Kupffer cells and endothelial cells [36]. Hepatocytes have 
also been reported to acquire antigen presenting skills [45] and are generally considered 
to be both the target and inducer of the innate immune response [41]. 
 
The liver has a remarkable regenerating capacity both via proliferation of hepatocytes 
[46] and via activation and differentiation of oval cells [47, 48]. Growth factors and 
cytokines, such as HGF (hepatocyte growth factor), TGF-β, FGF1, IL-6 and TNFα, 
released by Stellate cells and Kupffer cells respectively, has shown to have 
hepatoprotective effects and to stimulate liver regeneration [40, 42, 49-51]. 
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Additionally, TGFβ signaling, which under normal conditions keeps the hepatocytes in 
a quiescent state, is suppressed during injury [47].  
 
1.1.3.2 Oval cells 
Oval cells are adult hepatic progenitor cells, expressing markers of both hepatocytes 
and biliary cells. They populate the canals of Hering, the zone between the periportal 
hepatocytes and the biliary cells of the smallest intrahepatic bile ducts [52]. In a 
healthy human liver the oval cells are quiescent and present only in small numbers. 
Contrary, during severe and prolonged liver damage when hepatocyte proliferation is 
compromised, the oval cells are activated, start proliferating and infiltrate into the 
parenchyma, giving rise to both hepatocytes and biliary cells [42]. It has been shown 
that various cytokines, such as TNFα, released from Kupffer cells [53] may have a 
role in oval cell activation [42, 54]. Stellate cells have also been suggested to be 
involved in the proliferation and differentiation of oval cells by secretion of several 
potential hepatocyte mitogens, such as HGF [42, 49]. Oval cell maintenance and liver 
regeneration activities are also regulated by extracellular matrix components [55, 56]. 
In rats, cytokines such as OSM are shown to inhibit oval cell proliferation, inducing 
differentiation [57].  
 
1.1.3.3 Cholangiocytes 
Cholangiocytes are epithelial cells lining the hepatic bile ducts and via different 
secretory and absorptive processes they modify the composition, pH and fluidity of the 
bile [36]. They also have an active immunologic role in both the innate and adaptive 
immune responses by interacting with immune cells through expression of adhesion 
molecules and antigens. When activated by pro-inflammatory cytokines, like TNF-α 
and IL-6, they secrete chemoattractant cytokines, such as IL-8 and MCP-1 (monocyte 
chemoattractant protein 1) [58]. Many drugs that induce a hepatic toxic response or 
chronic inflammation, result in dysfunction of the bile formation and bile flow, 
ultimately leading to cholestasis [59]. 
 
1.1.3.4 Sinusoidal endothelial cells 
The hepatic sinusoids are lined by fenestrated endothelial cells. The basolateral surface 
of the hepatocyte is separated from endothelial cells by the space of Disse. The 
fenestration allows efficient transfer of proteins and other macromolecules between the 
blood and the hepatocytes. The fenestration also facilitates the communication between 
cells in the sinusoidal lumen and the hepatocytes as well as other cells in the space of 
Disse [41, 60]. The sinusoidal endothelial cells play an important role in the hepatic 
immune response as they participate in the clearance of antigens from the circulation 
by receptor mediated endocytosis, cytokine secretion and by antigen presenting 
capacities [60]. They also collect and present antigens originating from hepatocytes 
[41]. The regulation of endothelial antigen presentation and their role in induction of 
apoptosis of activated T cells play an important role for the immunologic tolerance in 
the liver [61]. 
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1.1.3.5 Stellate cells 
The hepatic stellate cells, or fat storing cells, are spindle-shaped cells located in the 
space of Disse, with extensions into the inter-hepatocellular space. They have an 
important role in storage and transportation of retinoids (vitamin A compounds) [62] 
and the have the ability to secret different components of the extracellular matrix 
(ECM), like collagen, proteoglycans and laminin, all essential for many hepatocellular 
functions [63]. Stellate cells also play a role in hepatic immunoregulation as they are 
known to express Toll-like receptors for LPS stimuli [64]. Activated stellate cells can 
amplify an inflammatory response in the liver by secretion of cytokines and 
chemokines [49] as well as by antigen presentation [65-67]. When activated, the stellate 
cells become depleted of vitamin A and via fibrogenic activities they start synthesizing 
large amount of ECM components, including collagen and adhesive glycoproteins [49, 
68]. Chronic liver injury may lead to overproduction of ECM by the stellate cells which 
ultimately results in liver cirrhosis [47].  
 
1.1.3.6 Kupffer cells 
Kupffer cells together with lymphocytes constitute the major part of the hepatic 
immune cells. Kupffer cells are resident liver macrophages with migratory, phagocytic, 
inflammatory and antigen presenting capabilities, believed to be derived from 
circulating monocytes [41, 69]. The major part of the Kupffer cells are found around 
the periportal veins where the cells are larger and more active in phagocytosis 
compared to those found around the central veins [70]. Kupffer cells reside in the 
sinusoids where they are in close contact with passing lymphocytes as well as with the 
hepatocytes via the space of Disse [41]. They constitute the first line of defense and 
their location provides effective clearance of endotoxins like LPS and other infectious 
agents and [71]. Thus, Kupffer cells have important regulatory function in the 
pathophysiological state of the liver. When activated they release a cascade of various 
pro- and anti-inflammatory mediators such as interferons, interleukins (i.e. IL-1β, IL-4, 
IL-6, IL-10), nitric oxide and reactive oxygen species (ROS) [40, 50, 72]. Moreover, 
Kupffer cells are the main hepatic producers of TNFα, an important mediator of liver 
injury [40]. Activated Kupffer cells also stimulate other immune cells, like natural 
killer (NK) cells and natural killer T (NKT) cells, as well as recruit neutrophils by 
secretion of the chemotactic cytokines, like IL-8 [73]. Kupffer cells may also stimulate 
hepatocytes to produce IL-8, further increasing the chemotactic response [74].  
 
1.1.3.7 Lymphocytes 
Liver resident lymphocytes are regarded liver specific and differ phenotypically from 
lymphocytes found in the general circulation [69]. They reside predominantly in the 
periportal regions and the composition of the lymphocytes populations vary both with 
age and gender [75, 76]. Lymphocytes play a key role in the adaptive immune response 
and usually require antigenic stimulation. Like Kupffer cells they can produce both pro- 
(mainly IFN-γ but also TNFα and IL-2) and anti-inflammatory cytokines (i.e. IL-4 
andIL-10) in response to agents, such as LPS [40, 69].  
 
Lymphocytes consist of three major cell types; NK cells, T cells, and B cells (Figure 2). 
The NK cells have spontaneous cytotoxic activities against tumors, bacterial-, parasite- 
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and virus-infected cells and are critical to the innate immune system [77, 78]. The NKT 
cells are the predominant T cell type and express the NK cell marker as well as other T 
cell receptors (i.e. the αβT or the γδT cell receptor), recognizing antigens in association 
with the HLA (human leukocyte antigens) class I molecules on antigen presenting cells 
[41]. NKT cells are also able to distinguish a more limited variety of antigens which is 
not HLA dependent, such as bacterial and viral non-peptide antigens [79]. NKT require 
the presence of cytokines such as IL-2 and IL-12 for activation of their cytotoxic [77, 
78]. NKT cells have been shown to scan the liver sinusoids by crawling within the 
sinusoids and stopping upon T cell antigen receptor activation [80]. The CD8+ 
cytotoxic T cells and the CD4+ helper T cells both display the αβ T cell receptor, 
recognizing antigens presented in association with HLA class I and class II molecules 
respectively. CD8+ cytotoxic T cells target virally infected cells and tumor cells, 
destroying them via release of various cytotoxins. Activated CD4+ helper T cells 
proliferate, differentiate and regulate different type of immune response such as 
maturation of B cells and activation of CD8+ T cells and Kupffer cells by secretion of 
various cytokines like IL-4, IL-5, IL-2, TNF-α and IFN-γ [81]. Importantly, T (and B) 
cells possess a “memory”, which makes them respond more vigorously when re-
exposed to the same antigen [82]. During non-inflammatory conditions, stimulation of 
sinusoidal endothelial cells and Kupffer cells do not induce a T cell response but rather 
induce the secretion anti-inflammatory cytokines, like IL-10, contributing to 
immunological tolerance [83, 84]. Activated B cells are antibody-secreting cells that 
reside only in small numbers in a healthy liver [41].  
 
1.1.4 Biotransformation in the liver 
The liver plays a crucial role in the metabolism of several endogenous substances but 
also of exogenous xenobiotics, such as medical drugs. Many drugs are lipophilic and 
require metabolism to increase their water solubility, facilitating excretion via bile and 
urine. Some drugs also require metabolism in order to generate the active 
pharmacological compound [36]. Hepatic biotransformation is generally divided in 
two processes: phase I and phase II reactions. Additionally, hepatic transporters are 
generally considered to constitute phase III processes and play crucial roles in drug 
absorption, distribution and excretion (Figure 3) [85]. Thus, metabolism is a multi-step 
process that involves multiple reactions [86]. Phase I reactions (mainly redox reactions) 
generally increases the polarity of the substrate and as a consequence these reactions 
often generate reactive intermediates that could be toxic to the cells [87, 88]. The 
oxidative phase I processes, mainly catalyzed by the cytochrome P450 enzyme family, 
are by far the most important reactions in drug metabolism and will be discussed in 
more detail later. Some phase I products are excreted but most undergo a subsequent 
phase II reaction where an endogenous substrate, such as glucoronic acid or 
glutathione, is added forming a polar conjugate. This generally renders a more water 
soluble and less reactive derivate that readily can be excreted [86, 89]. Thus, the status 
of the drug metabolizing enzymes influences the metabolite formation and, hence, the 
toxic capacity of the drug. Moreover, regulation of several phase I and phase II 
enzymes has been shown to alter the expression of many phase III transporters thereby 
affecting the excretion of xenobiotics [85]. 
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Figure 3. Hepatic biotransformation is generally divided in two processes; phase I and phase II 
reactions. Phase I reactions largely increase the polarity of the substrate, making the compound more 
reactive. Subsequent, phase II reaction often forms polar conjugates, which are less reactive and can be 
readily excreted. Additionally, transporters are generally considered as a phase III process since they 
play crucial roles in drug absorption, distribution and excretion. Many different factors may affect the 
expression of the enzymes and transporters involved in biotransformation of drugs. CYP, Cytochrome 
P450; ADH, Alcohol dehydrogenase; MAO, Monoamine oxidase; FMO, Flavin-containing 
monooxygenase; GST, Glutathione S-transferase; NAT, N-acetyltrasferase; UGT, UDP 
glucuronosyltransferase; OATP, Organic anion transporting polypeptide; MRP, Multidrug resistance-
associated protein; P-gp, P-glycoprotein; BCRP, Breast cancer resistance protein; BSEP, Bile salt export 
pump. 
 
 
1.1.4.1 Cytochrome P450s 
The cytochrome P450 superfamily are heme-containing enzymes [90-92] involved in 
the metabolism of a wide variety of endogenous and exogenous compounds, such as 
steroid hormones, fatty acids and medical drugs [93]. The CYP enzymes, localized in 
the endoplasmic reticulum and in the mitochondria, are mainly expressed in the liver 
but significant amounts are also present in the intestine, as well as in kidney and lung 
[94]. The CYP catalyzed reactions are dependent on molecular oxygen where one 
oxygen atom is reduced to water while the second oxygen atom oxidizes the 
substrate, rendering a more polar product. This process requires electron transfer from 
reduced NADP+, which is mediated mainly by cytochrome P450 reductase (POR), 
although in several cases cytochrome b5 has also shown to be involved [95, 96].  
 
The CYP enzymes are divided into different families, subfamilies and individual 
enzymes based on similarities in their amino acid sequences [97, 98]. The CYP 
enzymes belonging to family 1, 2 and 3 are the most important ones regarding 
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metabolism of drugs and other xenobiotic substances [87, 99] and are estimated to 
account for about 70-75% of all phase I metabolism of drugs used in the clinics [100, 
101]. Many of the most clinically relevant CYPs are highly polymorphic [102] which 
can result in altered enzyme activity and often translates into inter-individual 
differences regarding therapeutic effect and susceptibility to drug induced toxicity [100, 
103]. More information regarding genetic polymorphisms of the different CYP families 
and their phenotype can be found in “the human CYP allele nomenclature database” 
(http://www.cypalleles.ki.se). Apart from genetic variability, other factors such as age 
[104], gender [105], general health status [106] and concomitant usage of several drugs 
(both pharmaceutical and alternative) [100] may also affect CYP enzyme expression. 
Moreover, our metabolic phenotype is also affected by different environmental factors, 
such as our diet and lifestyle choices, i.e. cigarette smoking and alcohol consumption 
[106-108] (Figure 3). 
 
1.1.4.1.1 CYP3A4 
The human CYP3A genes, CYP3A4, CYP3A5 and CYP3A7 are the most abundant 
CYPs in human liver, accounting for about 30-40% of the total CYPs present [101, 
109] Evans 1999). CYP3A4 accounts for the larger part of the CYP3A enzymes [102, 
109] and is clinically the most important one. CYP3A7 is predominantly expressed in 
fetal liver [110]. CYP3A5 has similar substrate specificity as CYP3A4 but is only 
detectable in 20-30% of the human population where it generally is expressed in 
lower levels [110, 111]. CYP3A4 is involved in the metabolism of a wide range of 
endogenous substrates, such as steroid hormones [112, 113] and bile acids [114], but 
also many exogenous compounds [98]. Importantly, CYP3A4 is involved in the 
metabolism of about 50% of all marketed drugs, such as midazolam, verapamil, and 
simvastatin [111].  
 
CYP3A4 is a polymorphic enzyme [109, 115] and the large inter-individual variation 
has been suggested to be caused by alterations in the promoter region [116-118]. To 
date, more than forty allelic variants have been identified and some are reported to 
affect the function of the enzyme (http://www.cypalleles.ki.se), however, none are 
present at high enough frequency as to explain the inter-individual variation in catalytic 
activity seen in the human population [102]. It is more likely that the metabolic 
variability could relate to non-genetic factors such as health status, gender, diet and 
environmental factors [105, 106, 108]. CYP3A4 is also particularly susceptible to 
enzyme inducers, such as the antibiotic rifampicin and the herbal antidepressant St. 
John's wort, as well as inhibitors, like grapefruit juice and the antifungal drug 
ketoconazole [98, 119, 120]. Moreover, the level of induction can vary between 
individuals depending on the substrate [120]. Thus, drug toxicity due to altered 
CYP3A4 metabolic activity is relatively common in humans.  
 
1.1.4.1.2 CYP3A4 gene regulation 
The first 13 kb of the CYP3A4 5’-flanking region have been thoroughly analyzed 
regarding its regulation [121]. In this region three distinct elements have been identified 
to, in a  cooperative way, be important for the regulation of the gene; the proximal 
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promoter region (PROX), the xenobiotic-responsive enhancer module (XREM) [122, 
123], and the far distal constitutive liver enhancer module (CLEM4) [124] (Figure 4). 
Figure 4. Schematic figure of the 5’-CYP3A4 promoter containing three important regulatory regions; 
PROX, XREM and CLEM4. Adapted from paper V. 
 
 
The CYP3A4 gene is transcriptionally regulated by the cross-talk between various 
transcription factors [106, 125], such as the nuclear receptors PXR (pregnane X 
receptor, NR1I2) [126-128], CAR (constitutive androstane receptor, NR1I3) [129], 
VDR (vitamin D receptor, NR1I1) [130] and GR (glucocorticoid receptor, 
NR3C1)[131]. These nuclear receptors interact with multiple regulatory DNA sites 
within the promoter region of the CYP3A4 gene. Additionally, other liver-enriched 
transcription factors, such as hepatocyte nuclear factors (HNF) and CCAAT/enhance-
binding proteins (CEBP), are also important for CYP3A4 regulation and essential for 
the constitutive expression [106, 124, 132, 133]. HNF4α, in particular, is known to be 
an important player in the regulation of CYP3A4 by the interaction with PXR [124, 
132] but also for the transcriptional regulation of PXR [33].  
 
Recently a unique study was published showing highly variable CpG methylation 
frequencies in several important CYP3A4 transcription factor binding sites [134]. Two 
single CpG sites were identified as significantly associated with CYP3A4 expression 
[134], suggesting that epigenetic variations may be of importance for the inter-
individual differences in gene expression [102]. Moreover, Kacevska et al. showed that 
the methylation pattern for the CYP3A genes differed between adult and fetal livers 
[134], indicating that epigenetic modifications regulate the developmental switch. 
This is supported by a study done in mice where epigenetic histone modifications 
exhibited dynamic changes during liver development [135]. Several studies also report 
of post-transcriptional regulation of CYP3A4, both via direct targeting [136] but also 
via indirect targeting of CYP3A4-regulating transcription factors, such as PXR [137-
139] and VDR [136]. Additionally, CYP3A4 may also be subjected to ubiquitination 
and degradation via PKA/PKC mediated phosphorylation [140]. 
 
1.1.4.1.2.1  PXR 
PXR has one of the broadest ligand spectrums of the nuclear receptor superfamily with 
many endogenous substrates, such as steroids and certain bile acids, as well as 
exogenous compounds, like the antibiotic rifampicin. PXR is an important modulator of 
several key biochemical pathways, such as gluconeogenesis and beta-oxidation, and 
plays an important role in bile homeostasis by down-regulation of CYP7A1 [141, 142]. 
 
PXR is activated by many xenobiotic substrates and is vital for the 
metabolism/detoxification process [143]. PXR is a major transcriptional regulator of 
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CYP3A4 [126-128] but also of other important phase I genes, such as CYP2C [144] and 
CYP2B [145], phase II genes, like UGT1A1 [146], and membrane transporters, like 
MDR1 [147] and MRP2 [148]. Importantly, PXR is estimated to be the nuclear receptor 
responsible for about 60% of all undesirable, clinically relevant drug-drug interactions 
involving CYP3A4, consequently playing a major role in the development of ADRs 
[128, 141].  PXR has also been suggested to play an important role in the molecular 
mechanism that links xenobiotic metabolism and inflammation. It is well known that 
the enzyme activities of several CYPs, including CYP3A4, are negatively affected by 
inflammatory mediators, like IL-6 and TNFα [106], negative regulating transcription 
factors, such as PXR, possibly via the inflammatory mediator NF-κB (nuclear 
transcription factor kappa B) [106, 149]. 
 
It is generally considered that PXR induction is ligand dependent and that activated 
PXR is translocated from the cytoplasm to the nucleus where it interacts with the 
promoter region of its target gene as a heterodimer with RXR (retinoid X receptor). 
However, there are still different opinions regarding the subcellular localization of 
unliganded PXR [150-152]. PXR regulates CYP3A4 by binding to responsive elements 
composed of various repeats of the consensus motif AG(G/T)TCA. These repeats 
include direct repeats (DR) and everted repeats (ER) separated by different numbers of 
nucleotides [125]. PXR is known to bind strongly to an everted repeat separated by six 
base pairs (ER6) located in the PROX region [128], in the XREM region [122] and in 
the far distal CLEM4 region [153], as well as to direct repeats separated by 3 (DR3) or 
4 (DR4) base pairs the distal XREM region [122, 154].  
 
PXR regulation has been studied extensively but is far from being fully elucidated. The 
transcriptional activity of PXR is known to be regulated by different co-repressors, 
such as SMRT (silencing mediator of retinoid and thyroid receptors), COUP-TF 
(chicken ovalbumin upstream promoter transcription factor) and NcoR (nuclear 
receptor co-repressor) [155-157], as well as various co-activators, such as HNF4α 
[132], PGC-1 (Peroxisome proliferator-activated receptor gamma co-activator) and 
SRC-1 (steroid receptor co-activator) [158]. The differential recruitment of co-factors 
has shown to be ligand-dependent [159]. In addition, PXR has shown to be post-
transcriptional regulated by miRNA (miR-148a) [137] as well as by post-translational 
mechanisms, like ubiquitination [156], acetylation [155], phosphorylation by various 
kinases [138, 139, 160] and epigenetic regulation by protein arginine 
methyltransferase1 (PRMT1) [161]. Adding to the intricate regulation of PXR, several 
SNPs has been described for the PXR gene [123, 162, 163] along with various 
identified splice variants [107, 164, 165] which are suggested to play a part in the  
inter-individual variations in basal and inducible expression of CYP3A [150, 163, 
165]. 
 
 
1.2 HUMAN LIVER CELLS IN RESEARCH 
1.2.1 Primary hepatocytes 
Primary human hepatocytes generally express all the drug metabolizing enzymes and 
transporters found in human liver which makes these cells the closest model to the in 
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vivo liver. This is why primary hepatocytes are considered the golden standard in drug 
development and toxicological studies [166]. However, primary hepatocytes are 
phenotypically instable and when they are isolated from their in vivo microenvironment 
and put in 2D cultures they rapidly de-differentiate into in a population of adult liver 
progenitors [167], loosing many of their liver specific functions, in particular CYP 
enzyme levels [168]. In addition, 2D culture limits the survival of the cells to only 1-2 
weeks [169]. However, by culturing primary hepatocytes in a sandwich culture of 
collagen or matrigel, the hepatocyte life span, morphology and specific hepatic 
functions can be preserved for longer period of time [169, 170]. Unfortunately, the 
sometimes low availability of fresh human liver samples compromise the use of 
primary hepatocytes in routine testing. Moreover, the resected livers most often 
originate from medicated patients that may severely affect cell viability and specific 
functions. Regarding donated livers, the patients have often been subjected to various 
pharmaceuticals, e.g. for the treatment of brain injury, again potentially affecting the 
expression of various drug metabolizing enzymes [89]. Cryopreserved hepatocytes 
are often used as they are available and phenotypically characterized which facilitates 
their use in routine research [171]. Moreover, pooled cells from several donors are 
available which reduce inter-donor variability. However, these cells are expensive 
and share the same limitations as freshly isolated hepatocytes regarding loss of liver 
specific functions in culture.  
 
1.2.2 Hepatoma cell lines 
Due to the scarce number and limited proliferation potential of human hepatocytes 
along with high variability of drug metabolizing enzyme expression in different 
preparations, hepatocellular carcinoma-derived cell lines, such as HepG2 and Huh7, are 
frequently used to get insight in mechanistic pathways regarding metabolism and 
toxicity. Hepatoma cell lines are easy accessible, easy to culture and provide a cell 
source of high yield.  Moreover, they have a more stable phenotype which makes them 
more useable in routine testing [89]. However, these cell lines generally contain very 
low levels of drug metabolizing enzymes, such as CYPs [172], and often require 
modifications, like transfections and/or enzyme induction [168, 173]. Lately a new 
hepatoma cell line, HepaRG, was generated. After DMSO treatment these cells has 
been shown to differentiate into a mixed cell population of both hepatocyte- and 
biliary-like cells [174] with pronounced expression of some CYPs, UGTs and 
transporter activities [175, 176]. 
 
1.2.3 Stem cells 
Stem cells are undifferentiated (unspecialized) cells with the ability to develop into 
many different types of cells and they possess unlimited replication capacity [177]. 
Generally there are two different types of stem cells, embryonic and somatic (adult) 
stem cells, with different characteristics and potentials [177]. Recently, researchers 
have been able to successfully reprogram fully differentiated somatic cells into cells 
with stem-cell like properties, called induced pluripotent stem cells (iPSC) [178]. 
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1.2.3.1 Embryonic stem cells 
The breakthrough for stem cell research came about 30 years ago with the first 
successful isolation of an embryonic stem cell line from a mouse embryo [179, 180]. In 
1998, the first generation of an in vitro, multi-passaged, culture of human embryonic 
stem cells (hESC) was reported [181] and since then many different protocols have 
been developed for the establishment, propagation and characterization of hESC. 
Embryonic stem cells represent the inner cell mass of the blastocyst in the earliest stage 
of the embryo development and are characterized by the expression of various 
transcriptional factors such as OCT-4 (octamer-binding transcription factor 4) [182], 
SOX2 [183] and NANOG [184] (Figure 1). These cells are pluripotent and can 
generate all three germ layers, thus capable of differentiating into any kind of cell in the 
human body [181, 185]. With these unique properties, these cells provide a highly 
interesting model system for basic research on embryonic and organ development, as 
well as a hepatic cell source for drug discovery and toxicology studies [186, 187]. In 
the future, these cells might also be used in clinical therapies [186, 188]. During the 
recent years, much effort has been put into the development of effective protocols for 
hepatic differentiation of hESCs, largely based on what is known about the 
embryogenesis (Figure 1) [167, 187, 189-193]. 
 
1.2.3.2 Hepatic somatic stem cells 
Somatic stem cells have a more limited differentiation potential compared to hESC but 
has an important role in tissue homeostasis and injury repair in the multicellular 
organism [177]. The presence of hepatic stem cells (oval cells) were first discovered in 
fetal mice livers [194] and was later also isolated from human adult livers [195]. Oval 
cells are multipotent stem cells that can give rise to both hepatocytes and biliary cells 
[42]. Hepatic oval cell lines have been generated that retain the progenitor cell features 
expressing markers for both cholangiocytes and hepatic progenitors after long term 
cultivation and serial passages [196]. These cells might thus serve as an expandable 
hepatic cell source for research and for cell-based therapy [197, 198].  
 
1.2.3.3 Induced pluripotent stem cells 
In 2006, a Japanese research group successfully reprogramed adult mouse fibroblasts 
into induced pluripotent stem cells (iPSC) by introducing four transcription factors: c-
Myc, Oct3/4, Sox2 and Klf4, by retroviral transduction [178]. A similar approach was 
also successfully performed with human fibroblasts (Takahashi 2007) and later using 
other cell types from both human and mouse [199]. The iPSC are stem cell-like 
regarding morphology and characteristics, such as pluripotency and genetics, 
expressing a number of stem cell biomarkers [199]. Several groups have subsequently 
been able to successfully generate hepatocyte-like cells from iPSC [200-202]. The 
iPSC technology is promising with a future potential in patient- and disease-specific 
therapy [199]. However, in order for these cells to be used in a clinical application 
several important issues has to be addressed, such as somatic origin memory, donor-
dependent variations, low reprogramming efficiency, risk of potential teratoma 
formation, safety concerns regarding transduction delivery methods and the presence 
of transgenes, like oncogenes [199, 203].  
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1.3 DRUG INDUCED LIVER INJURY  
DILI represents a major challenge for the public health care as well as for the 
pharmaceutical industry. Liver injury is a serious ADR, estimated to account for about 
half of all cases of acute liver failures, a lethal condition that often requires liver 
transplantation [204]. Even though paracetamol poisoning (intentional and 
unintentional) accounts for the major part of DILI [13], as much as 16% of all acute 
liver failures are of idiosyncratic nature making DILI one of the most commonly 
reported ADR [205, 206]. Contrary to intrinsic (dose-dependent) drug reactions, 
idiosyncratic drug reactions only occur in a small subgroup of patients, are usually 
independent of dose and often have long latency periods [13]. Due to safety 
regulations, a new compound has to be validated in both in animals (in vivo) and in 
cell models (in vitro) before entering clinical testing. However, idiosyncratic reactions 
are usually not predicted by the pre-clinical models or even during pre-marketing 
clinical trials [207]. During the last decade’s, toxic effects on the liver has been one of 
the most cited reasons for regulatory actions concerning drugs, including boxed 
warnings and restricted marketing [9, 208]. Additionally, in a report from 2003 it was 
estimated that as much as 50% of all approved drugs withdrawn from the market were 
related to toxic effects on the liver [206].  
 
1.3.1 Immune mediated hepatotoxicity 
There are many drugs on the market today, i.e. diclofenac and flucloxacillin, that are 
known to have associations with DILI in certain patients and it has become 
increasingly evident that inflammatory event plays a significant role, involving both the 
innate and adaptive immune system [13]. Many different factors may trigger an 
immunological response and influence the toxicological outcome during drug 
treatment: the levels of reactive metabolites formed causing stress and/or cell damage 
[100], adducts generated by binding of the drug or metabolite to cellular proteins and 
macromolecules or an underlying infection [209].  
 
The Kupffer cells are known to be especially important in the progress of DILI [13]. 
Kupffer cells respond to bacterial endotoxins, like LPS, via the TLR4 (toll-like 
receptor) expressed on most liver cells [41]. The activation results in the production of 
a range of inflammatory mediators, such as cytokines and ROS. Some of these 
mediators, like IL-10 and IL-6, may work in a hepatoprotective manner whereas some, 
such as and TNFα and IL-1β, often contribute to the progression of liver injury where 
other cells are activated, adding on to the immunological response [82]. TNFα released 
from activated Kupffer cells may also induce apoptosis and necrosis in hepatocytes via 
production of nitric oxide and ROS as a result of mitochondrial dysfunction [209]. 
During liver insult, targeted cells, such as hepatocytes and sinusoidal endothelial cells, 
have the ability to present antigens to lymphocytes which adds to the immune response 
by the activation of the cytotoxic cells but also of memory cells which may potentiate 
the response whenever re-challenged with the drug [41, 210].  
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During the recent years, a number of idiosyncratic DILI-related drugs have shown 
striking association with specific HLA alleles (Table 1). HLAs are cell surface 
glycoproteins with the role to present peptide antigens to T cells, thus playing an 
essential role in the innate and adaptive immune system [36]. The HLA class I 
proteins (i.e. A, B, and C) are expressed on most cell types and presents antigens that 
mainly activates CD8+ cytotoxic T cells. HLA class II proteins (i.e. DR, DQ, and DP) 
are generally expressed on antigen presenting cells and often activate CD4+ T helper 
cells. The HLA molecules are highly polymorphic with allele frequencies that vary 
between different populations and ethnic groups which causes inter-individual 
variability in susceptible to certain pathogens [211]. For some drugs FDA (US Food 
and Drug Administration) has even suggested screening of patients for specific HLA 
alleles before use, as done for carbamazepine (HLA-B*15:02) and abacavir (HLA-
B*57:01) to avoid hypersensitivity reactions [212]. 
 
 
HLA Allele Compound Therapy area Odds ratio Reference 
B*57:01 Flucloxacillin Antibiotic 80.6 [213] 
DRB1*07:01- 
DQA1*02:01 
Ximelagatran 
 
Anticoagulant 4.4 [214] 
DRB1*15:01- 
DQB1*06:02 
Co-amoxiclav Antibiotic 2.8 
 
[215] 
DRB1*15:01- 
DQB1*06:02- 
DRB5*01:01- 
DQA1*01:02 
Lumiracoxib COX-2 inhibitor 5.0 [216] 
     Table 1. DILI- related drugs associated with specific HLA alleles in Caucasians. 
 
 
1.3.2 In vitro methods to study DILI 
Mono-cultures of primary hepatocytes are the most frequent used liver-specific in 
vitro model for drug metabolism and toxic evaluation [166]. These cell systems are 
valuable models as they possess the essential enzymes and transporters for the 
biotransformation pathways [217]. However, due to scarce availability of human liver 
tissue, hepatocytes of animal origin and cell lines are also frequently used with 
evident advantages with respect to their availability. Additionally, immortalized 
human hepatocytes with stable overexpression of various CYPs have also been 
described [204]. While these cell models are valuable for drug screening and toxicity, 
they do not always extrapolate to human biology. Due to limitations such as low 
metabolic capacity, species-specific mechanisms and inadequate extra-cellular milieu, 
the in vitro cell systems used today have rather low prediction of DILI.  
 
Primary hepatocytes are highly dependent on tight cell-cell contact and organized 
cellular architecture, not only for the maintenance of their differentiated functions and 
organized tissue architecture, but also for the regulation of their proliferation status 
[218, 219]. So far, precision-cut tissue slices best meet this requirement where the 
organ structures are maintained together with expression of phase I and II enzymes and 
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required co-factors [220]. This culture technique has been further improved by 
continuous medium exchange [221], however, due to special technical requirements 
and skills together with the low availability of freshly human liver tissue, this method 
has limited applications. During the last decade several promising 3D culture systems 
have been developed, designed to better mimic the physiological conditions in the liver, 
with the aim to retain the hepatic functions of primary hepatocytes. Some examples are 
the use of various scaffolds [222, 223], bioreactor cultured spheroids [224, 225] and 
hollow fiber bioreactors [226-228] which all show improved hepatocyte function and 
maintenance, although with varying results. Many of these culture systems are perfused 
providing the cells with a continuous supply of nutrients and oxygen, important factors 
since the hepatocytes are highly susceptible to oxygen and nutrient limitations [226].   
 
DILI is caused by multiple complex mechanisms and apart from the metabolic aspects, 
toxic onset after drug treatment often involves the interplay between several different 
types of cells [13]. Co-cultures between hepatocytes and epithelial cells [229] or 
hepatocytes and fibroblasts [230] have shown to improve the expression of 
biotransformation enzymes of hepatocytes in culture. Moreover, co-culture of primary 
hepatocytes and hepatic stellate cells [231, 232], hepatocytes and macrophages [233] 
and macrophages and cholangiocytes [234] have also been developed. All have been 
able to show toxic mechanistic interactions which might not have been achieved using 
conventional hepatocyte mono-cultures. This supports the fact that in order to study the 
relevant in vivo mechanisms, more advanced in vitro cell systems has to be developed, 
where cellular interaction, architecture and integrity is better preserved. 
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2 AIM 
The aim of this thesis was to refine and further develop more sensitive, human, in vitro 
models and methods for better prediction of drug induced liver injury and the 
underlying mechanisms. The work presented here constitutes of two different parts:  
 
 
1) To generate new sources of functional human hepatic cells.   
 
• Cell-cell contact-promoted differentiation of the human hepatoma cell line 
Huh7 has been investigated.  
 
• A stepwise, directed, differentiation protocol has been evaluated for hepatic 
differentiation of human embryonic stem cells. 
 
 
2) To develop and evaluate new in vitro cell culture models to improve and 
maintain the hepatic functionality of the cells, better extrapolating to human 
liver biology.  
 
• A human co-culture model, incorporating hepatocytes and monocytes, has been 
developed to evaluate the inflammatory aspects of drug induced liver injury. 
 
• Metabolically active Huh7 cells have been generated to study the endogenous 
regulation of CYP3A4.  
 
• A dynamic bioreactor system has been used for the evaluation of three-
dimensional culture in the hepatic differentiation of human embryonic stem 
cells.
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3 COMMENTS ON EXPERIMENTAL METHODS 
3.1 CELLS  
3.1.1 Human primary hepatocytes and liver tissue 
Human liver tissue and primary hepatocytes used in in papers II, III, and IV were 
obtained from Sahlgrenska university hospital (Gothenburg, Sweden) and Karolinska 
university hospital (Huddinge, Sweden), originating from patients undergoing liver 
resection. All tissues were obtained by qualified medical staff, with donor consent 
and ethical approval. In paper II, purchased cryopreserved hepatocytes were used and 
plated on Collagen I coated cell culture dishes according to the manufacturer’s 
instructions (In vitro Technologies).  
 
3.1.2 Cell lines 
In this thesis the monocytic cell line THP-1 (paper I) and the human hepatoma cell 
lines Huh7 (papers I, III and V) and HepG2 (paper III) were used and cultured 
according to manufacturer’s instructions. The HepG2 cell line (ATCC) originates from 
15 year old Caucasian American male [235] and the Huh7 cell line (HSRRB) from a 57 
year old Japanese male [236], both with a well differentiated hepatocellular carcinoma. 
The THP-1 cell line (ATCC) was derived from a 1 year old male with acute monocytic 
leukemia [237]. 
 
3.1.3 Stem cell culture and differentiation 
The human embryonic stem cell lines (hESC), used in papers II and IV (Cellectis Stem 
Cells, Cellartis AB), were derived from surplus human embryos from clinical in vitro 
fertilizations and characterized as previously described [238, 239]. The undifferentiated 
cells was cultured as a monolayer on mitotically inactivated mouse embryonic 
fibroblasts (MEFs) [238, 239] or under feeder-free conditions and enzymatically 
passaged regularly according to Cellectis defined culture protocols. By directed 
differentiation via definitive endoderm (DE), hepatic progenitors (PRO) and finally to 
hepatocyte-like cells (HEP), the developmental phases seen in vivo were mimicked. 
The induction of hESC into DE was initiated by a 24h pre-treatment in Cellectis 
proprietary pre-treatment medium, followed by a media containing various additives, 
such as Activin A and sodium butyrate. On day 7, the generated DE cells were 
passaged and cultured for 3 days in progenitor medium supplemented with FBS and 
growth factors BMP2 and 4, FGF1 and FGF2, followed by a serum-free media 
containing dimethyl sulfoxide (DMSO). On day 12 the PRO cells were passaged and 
further matured into hepatocyte-like cells by culturing in medium containing various 
supplements like Oncostatin M, HGF, dexamethasone, DMSO, insulin, and hEGF 
(human epidermal growth factor). For the 3D culture experiments the DE and PRO 
cells were inoculated in the bioreactor, on day 7 and 12 respectively. DE and PRO cells 
were also seeded in conventional matrigel-coated 2D cultures for parallel culture 
throughout the differentiation process.  
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3.2 IN VITRO CELL CULTURE MODELS 
3.2.1 The co-culture model 
In paper I we evaluated if the incorporation of monocytes in hepatocyte cultures could 
generate a more sensitive in vitro system for drug hepatotoxicity studies. Kupffer cells, 
derived from monocytes, are known to be involved in the development of drug-induced 
hepatotoxicity by the release of both pro- and anti-inflammatory mediators [240, 241]. 
We created a human co-culture system consisting of the hepatoma cell line Huh7 and 
the monocytic cell line THP-1 (Figure 5). Since there were no human Kupffer cell lines 
available at the time of the study, the THP-1 cell line was used. The Huh7 cells were 
seeded as an adherent monolayer in 12-well plates (Costar®) and after 24h the non-
adherent THP-1 cells were seeded into a Transwell® insert with a 3µM porous 
polyester membrane (Sigma-Aldrich), physically separating the two cell types by 1 mm 
but allowing molecules to passively diffuse. The insert-model proved to be superior to 
other models we tested (cells in direct contact or separated by a layer of collagen) since 
it allowed the cells to be evaluated separately. Moreover, the THP-1 showed to be more 
responsive to troglitazone treatment in the insert model as evaluated by the expression 
of TNFα. The ratio between the Huh7 and THP-1 cells was titrated in attempt to take 
the in vivo ratio into account.  A ratio of 2.5:1 (Huh7:THP-1) was used  based on the 
amount of 100% confluent Huh7 cells and the lowest amount of THP-1 cells from 
which RNA could be extracted. The cells were cultured in a 1:1 mix of each medium.  
  
 
Figure 5. Schematic illustration of the co-culture model. The huh7 cells were seeded adherent in the 
bottom of the well. The THP-1 cells were seeded non-adherent in an insert with a 3µM porous 
membrane, separating the two cell-types by 1 mm. Figure from paper I. 
 
 
A pair of thiazolidinediones was used as model drugs: Troglitazone (Rezulin®, 
Resulin® or Romozin®) and Rosiglitazone (Avandia®, Avandamet®, Avandaryl®). 
These drugs were developed for treatment of diabetes, sensitizing the action of insulin 
by acting as ligands for the nuclear peroxisome proliferator-activated receptor-γ 
(PPARγ) [242]. While rosiglitazone is not considered hepatotoxic, troglitazone has 
proved to cause idiosyncratic, hepatocellular injury in humans and was withdrawn from 
the market in 2000 [212].  
 
3.2.2 The three-dimensional (3D) bioreactor technology 
The multi-compartment, hollow fiber, bioreactor technology (Stem Cell Systems) [243] 
used in paper IV was originally developed for the clinic as a large-scale, bioartificial, 
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liver support system and has successfully been used to support the liver function of 
patients with acute liver failure [244]. The bioreactors consist of three independent 
bundles of hollow fiber membrane capillaries, interwoven into a 3D network which is 
enclosed by a polyurethane housing. The cells are inoculated in the cell compartment 
around the extra capillary space. Two of the capillary bundles are made of porous 
semipermeable polyethersulphone membranes for media perfusion and the third 
bundle consists of hydrophobic multilaminate membranes to enable gas exchange. In 
our lab, two lab scale bioreactors have been used with cell compartment volumes of 2 
ml (Figure 6A) and 0.5 ml (Figure 6B), respectively. The bioreactor is connected to 
medical-grade, polyvinyl chloride tubing, creating a circuit that is integrated in a 
perfusion device (Figure 6C) where several bioreactor systems may be run in parallel. 
Peristaltic pumps generate a continuous flow of media through the bioreactor, 
removing waste products and providing the cells with nutrients and gas in a 
decentralized way and with high mass exchange rate which is of more physiological 
significance. Fresh medium is continuously added to the circuit and mixed with 
recirculating medium. A sample port allows sampling from the reticulating medium but 
also the addition of substrates to the circuit. The perfusion devise also maintain 
controlled culture conditions for the cells regarding temperature (37ºC), oxygenation 
and pH regulation (by CO2) which may be adjusted manually. 
 
Figure 6. The three-dimensional, perfused, bioreactor technology [243]. The multi-compartment, 
perfused, hollow fiber bioreactor with a A) 2 ml or B) 0.5 ml cell compartment. 1) Cell compartment. 
Connections for 2) medium and 3) gas perfusion. 4) Port for cell inoculation. Filled arrows show 
direction of medium flow through the bioreactor, the red and the green each representing a separate 
bundle of capillaries. The dotted arrow indicates the gas flow through the bioreactor. C) The perfusion 
system with two separate bioreactors mounted. The bioreactors are connected to tubing for medium 
recirculation. 1) Speed-adjustable peristaltic pump units. 2) Bottles for addition of fresh medium and 3) 
collection of waste medium.  4) Sampling ports that enable sampling as well as injection of substrates. 
The temperature within the perfusion circuit is maintained at 37ºC. 5) The gas supply (air and 5% CO2) 
may be manually regulated by a gas mixing unit. 
Louise Sivertsson 
22 
3.3 GENE EXPRESSION ANALYSIS 
3.3.1 Real-time PCR 
Real-time polymerase chain reaction (RT-PCR) is a sensitive and quantitative method 
to determine the expression of certain genes in a sample. Gene specific primers 
containing fluorescent molecules are used and the progress of the PCR reaction can be 
monitored by the fluorescence intensity where the amount of fluorescence is directly 
proportional to the number of transcripts in the starting material. In this thesis two 
different real time methods have been used. In the SYBR Green method used in paper 
I, a non-specific, instable, fluorescent molecule were used that intercalates with the 
double-stranded DNA formed during the RT-PCR reaction. The binding of the 
molecule to the DNA changes the configuration of the SYBR Green and it starts 
emitting fluorescence. The TaqMan assay used in papers II, III, IV and V contains a 
sequence-specific oligonucleotide probe labeled with a fluorescent reporter. The probe 
is quenched when it is intact but during the PCR reaction when the gene-specific 
double stranded product is formed, the quencher is cleaved away and the probe starts 
emitting fluorescence. The TaqMan method is more sensitive since only the 
amplification of the target gene is detected whereas the SYBR Green molecule also 
binds to unspecific targets such as primer-dimers. The relative quantification of the 
different genes investigated was determined by adjusting the amount of transcript to 
housekeeping genes such as GAPDH and TBP. The relative levels in the samples 
compared with levels in control samples were defined by the comparative CT (2-∆∆Ct) 
method as described by Livak and Schmittgen [245].  
 
3.3.2 PCR Arrays 
The PCR Arrays are medium-throughput RT-PCR assays that generate several different 
gene-specific products under uniform cycling conditions. The TaqMan Low Density 
Array (Applied Biosystems) used in paper III can simultaneously perform 12 to 384 
TaqMan RT-PCR reactions pre-loaded in a microfluidic card format. These arrays can 
be custom made to include any TaqMan gene expression assay and each array can 
evaluate up to eight samples at the same time. The RT² Profiler PCR Array (Qiagen) 
used in paper I is a SYBR Green-optimized 96-well plate assay designed for the 
investigation of a panel of specific pathway-related genes. The relative quantitation of 
the individual target genes was generated using the comparative CT method as 
described above. 
 
3.3.3 Affymetrix array 
With the use of the microarray technology the expression of thousands of genes can be 
monitored simultaneously in a sample. Several different types of microarrays exist on 
the market. In papers IV and V we used the Affymetrix human GeneChip® ST (Sense 
target) 1.0 and 1.1 whole transcript arrays, respectively. These Affymetrix arrays are in 
situ synthesized, miniaturized, oligonucleotide probe arrays [246] with millions of 
immobilized, well-annotated, exon based probes which are designed to be distributed 
throughout the entire length of each transcript [247]. The principle behind the 
microarray technology is base pairing of two complementary sequences, the 
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immobilized probe on the array and the mobile target transcripts in the sample. The 
general procedure for a gene array experiment involves the conversion of the sample 
RNA to fluorophore labeled cDNA via reverse transcription. The labeled cDNA is then 
hybridized onto the array and scanned. The fluorescence intensity, directly proportional 
to the number of transcripts corresponding to each gene, is detected and the expression 
level of the gene is quantified. The obtained data was analyzed using DAVID 
(Database for Annotation, Visualization, and Integrated Discovery, 
www.david.niaid.nih.gov) in order to interpret the data in a more biological way [248, 
249]. The microarray technology has had a remarkable impact on gene expression 
analysis since it was developed in the early 1990s. However, there are several issues to 
be aware of when using this technology that might bias the final result. Some examples 
are: relatively poor sensitivity in detecting low expressed transcripts, cross-
hybridization, cross-platform inconsistency and variations in experimental procedure 
[250]. 
 
 
3.4 SUBCELLULAR FRACTINATION 
3.4.1 Microsomes 
Microsomes used in papers III and V consist of fragmented endoplasmic reticulum, the 
site where most of the drug metabolizing CYPs is located, which makes the 
microsomes a valuable tool for in vitro research regarding drug metabolism and drug-
drug interactions. For preparation of microsomes the cells were lysed in buffer 
containing glycerol for maintaining the structure and activities of the proteins. The 
homogenate were centrifuged at 10,000 x g for removal of undisrupted cells, nuclei and 
mitochondria. The microsomes were then isolated from the supernatant by precipitation 
at 100,000 x g centrifugation [251]. 
 
3.4.2 Nuclear and cytoplasmic extracts 
Nuclear and cytosolic extracts from cultured hepatoma cells were used in paper V. The 
cells were washed and re-suspended in hypotonic buffer to swell the cells and the cells 
were then lysed using the detergent NP-40. The nuclei were collected by centrifugation 
and the supernatant was saved as the cytosolic extract. After incubation of the nuclei in 
a high salt buffer and subsequent centrifugation the nuclear extract was collected. 
 
 
3.5 CLONING AND TRANSIENT TRANSFECTION 
In paper V, the CYP3A4 regulation was studied by the use of reporter constructs 
containing the three CYP3A4 5’-flanking regulatory regions; PROX (P), XREM (X) 
and CLEM4 (C). The different promoter constructs were created by PCR with a 
plasmid containing the -12.5 kb to +51 5’-promoter region of CYP3A4 [252] as a 
template. The regions were inserted in a pGL3 basic vector (Promega) using different 
restriction sites and the various constructs were verified by DNA sequencing. The full 
length promoter construct CYP3A4-PXC-luc containing all three regulatory regions is 
shown in figure 7.  
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For the plasmid transfection experiments, lipofection by Lipofectamine™ LTX with 
PLUS™ Reagent (Invitrogen) was used. During lipofection, nucleic acids are 
introduced into the cell with the use of a cationic lipid formulation that forms liposomes 
by binding with the nucleic acids. The liposome merges with the phospholipid bilayer 
of the cells, releasing the nucleic acid into the cell. The firefly luciferase enzyme was 
used as the construct reporter gene and co-transfected with a plasmid encoding the 
Renilla luciferase enzyme as a reference for normalization of the gene expression. For 
the gene silencing experiments in paper V, siRNA transfection was done using 
DharmaFECT1 (Thermo Scientific) containing lipids specially formulated to deliver 
siRNA. The cells were treated with target specific siRNA or a non-targeting siRNA 
pool as a negative control. Soon after being introduced into the cell, the ~20 bp long 
double-stranded siRNA molecules activate the RNA-induced silencing complex 
(RISC). Guided by the antisense strand of the siRNA, RISC degrades the targeted 
mRNA, preventing the synthesis of the protein, thus silencing the target gene.  
 
Figure 7. Schematic illustration of the CYP3A4-PXC-luc reporter construct containing three important 
regulatory regions in the 5’-CYP3A4 promoter; the PROX, XREM and CLEM4 site. 
 
 
3.6 IMMUNOLOGICAL TECHNIQUES 
In papers II, III, IV and V, proteins were visualized by different immunofluorescent 
techniques using antibodies that bind to the epitope of a specific protein. Secondary 
antibodies, conjugated to horseradish peroxidase or a fluorophore were then used to 
recognize the primary antibody using chemiluminescent or fluorescent techniques. 
 
3.6.1 Immunoblotting 
The denaturated proteins were separated on a SDS-polyacrylamide gel by 
electrophoresis (SDS-PAGE) depending on the length of the charged polypeptide [253, 
254]. The proteins were then blotted to a nitrocellulose membrane and detected using 
antibodies that were visualized by chemiluminescence. 
 
3.6.2 Immunohistochemistry 
The samples from the bioreactor were treated with formaldehyde, cross-linking the 
proteins. Fixation with formaldehyde may alter the antigenicity of proteins and might 
require antigen retrieval, unblocking the cross-linked proteins. The tissue was 
dehydrated with increasing concentrations of ethanol followed by xylene which is 
miscible with the paraffin embedding media. After paraffin embedding the sample was 
sectioned. In order to allow water soluble dyes to penetrate the sections, the paraffin 
wax was removed and the sample rehydrated. Selected antibodies were then used to 
visualize certain protein by fluorescence. The sections were routinely stained 
hematoxylin and eosin for visualization of nuclei and cytoplasm, respectively. 
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3.6.3 Immunocytochemistry 
Immunocytochemistry, a similar method as immunohistochemistry, was used to 
determine the presence and subcellular localization of specific proteins or antigens in 
the cultured cells. The cells were grown on cover slips, fixed in formaldehyde, and 
permeabilized using Triton X-100. The proteins were then detected using fluorescent 
conjugated antibodies and the nucleus was visualized with DAPI (4, 6-diamidino-2-
phenylindole) staining. 
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4 RESULTS AND DISCUSSION 
4.1 NOVEL HUMAN IN VITRO CULTURE SYSTEMS WITH INCREASED 
SENSITIVITY FOR DRUG-INDUCED CYTOTOXICITY – PAPER I 
The mechanisms by which DILI develop are complex. Apart from a direct cytotoxic 
effect, drug induced liver injuries often involve the interplay between several different 
types of cells [13]. Although mono-cultures of primary hepatocytes or HepaRG cells 
are valuable tools for drug screening and drug induced hepatotoxicity, high metabolic 
capacity does not always correlate with high sensitivity [255]. There are a growing 
number of in vivo studies showing that inflammatory mediators play a central role in 
the idiosyncratic potential of certain drugs, Kupffer cells being particular important in 
these processes. The role of Kupffer cells in DILI has elegantly been shown in several 
animal studies where inactivation of Kupffer cells with gadolinium chloride prevents 
the hepatotoxic effect exerted by different drugs and toxins, such as paracetamol 
[240] and carbon tetrachloride [241]. The release of TNFα from activated Kupffer 
cells has also been shown to be a key factor in the progression of alcoholic-induced 
liver disease in rats [256, 257].  
 
4.1.1 Co-culture set-up 
Previously, co-culture systems of endotoxin-stimulated, non-parenchymal cells 
together with hepatocytes from rat were shown to sensitize the hepatocytes and affect 
the hepatic protein synthesis, mediated via soluble factors produced by the non-
parenchymal cells [233, 258]. In order to evaluate whether the introduction of 
inflammatory cells could increase the sensitivity for drug-induced cytotoxicity we 
developed an in vitro co-culture system [232] based on hepatocytes and monocytes. 
Animal studies have poor predictively of DILI in man, thus a human in vitro system 
was desirable. Since no Kupffer cell lines were available at the time of the initiation of 
the study the human monocytic cell line THP-1 was used and co-cultured together with 
the human hepatoma cell line Huh7. As model drugs a pair of PPARγ agonists, 
troglitazone and rosiglitazone, were used. Troglitazone was withdrawn from the 
market in 2000 due to idiosyncratic hepatocellular hepatotoxicity in patients, whereas 
rosiglitazone is generally not considered to cause liver insult [212]. A concentration of 
troglitazone that caused modest cytotoxicity was chosen based on dose titration 
evaluation in single cultures. Three different variants of the co-culture system were 
evaluated: a model where the two cell types were cultured in direct contact with each 
other, a model where the cells was separated by a thin layer of collagen and an insert 
model where cells were separated by a thin porous membrane. The insert model 
(Figure 5) [232] was found to yield the highest sensitivity with respect to cell viability 
and the expression of inflammatory mediators and was therefore chosen for the study.  
 
4.1.2 Increased sensitivity for troglitazone-induced toxicity in the co-culture 
system 
Troglitazone treatment resulted in a modest cytotoxic effect in the single cultures but 
the toxic response was significantly potentiated in the co-culture with the viability 
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decreasing to about 40% for both cell types. Moreover, the toxic onset was generally 
faster in co-cultures compared to single cultures and was especially evident for the 
THP-1 cells, suggesting a synergistic cytotoxic effect by soluble mediators released 
between the cells. An initial screening experiment of the gene expression in 
troglitazone and rosiglitazone treated co-cultures identified several stress related 
pathways that was analyzed more in depth. RT-PCR analysis showed that troglitazone 
treatment induced several stress related, such as metallothionein 2A (MT2A), DNA 
damage-inducible transcript 3 (DDIT3), the chemokines CXCL2 and CXCL10 and heat 
shock protein A6 (HspA6), in the Huh7 cells from the co-culture compared to the Huh7 
treated in single culture. Similar results were observed regarding DDIT3, MT2A, 
CXCL2 and CXCL10 in troglitazone treated THP-1 cells in co-culture compared to the 
THP-1 single cultures. Moreover, troglitazone treatment also induced the expression of 
IL-1β in the THP-1 cells from the co-culture. Contrary, the gene expression of TNFα 
and IL-6 in THP-1 cells was significantly higher in single cultures compared to co-
cultures after troglitazone treatment. This suggests that the hepatocytes may have a 
modulatory effect on the responses of the non-parenchymal cells in this model, as 
supported by a study by Steinhorn et al. where they show that the LPS-stimulated 
secretion of IL-6 by rat non-parenchymal cells was decreased in co-cultures with 
hepatocytes [259]. In contrast to troglitazone, no toxic effects were detected in either 
cell type in the rosiglitazone treated co-cultures and single cultures. 
 
4.1.3 The hepatotoxic mechanism of troglitazone  
Several different mechanisms are suggested to cause the idiosyncratic effects observed 
in troglitazone treated patients. Troglitazone has been shown to induce apoptosis in 
hepatocytes and has been strongly associated to mitochondrial dysfunction caused by 
decreased ATP levels, mitochondrial DNA damage, loss of mitochondrial potential and 
increased levels of reactive oxygen species (ROS) [242, 260-262]. Indeed, DDIT3 
expression, known to be regulated by mitochondrial oxidative stress, was up-regulated 
in our troglitazone treated cells [263] which is supported by a study in primary 
hepatocytes showing that DDIT3 expression is increased after troglitazone treatment 
[264]. The troglitazone-induced mRNA expression of MT2A, known to be affected by 
oxidative stress due to mitochondrial deficiencies, was also observed in both cell types 
of the co-culture system [265]. Mitochondrial Hsp60 (heat shock protein 60) has both 
pro-and anti-apoptotic properties and may promote caspase 3 signaling [266].  In line 
with the ROS theory, a paper by Rachek et al. showed that the troglitazone-induced 
toxicity could be reduced by antioxidants [242]. In our cells a significant increase in 
catalase gene expression was seen in Huh7 cells in response to both PPARγ-agonists 
and was generally higher expressed in the co-cultures compared to the single cultures. 
Treatment with antioxidants, such as catalase and Trolox, only had low effects on the 
troglitazone-induced toxicity in our cells indicating that ROS only play a minor role. 
However, there are reports that suggest that traditional antioxidants may not be 
sufficient to protect against mitochondrial damage [267].  
 
Troglitazone is mainly metabolized to sulfate and glucuronide conjugates which are not 
considered to be hepatotoxic, however, reactive metabolites have also been found in 
patients treated with troglitazone [212]. Troglitazone has been suggested to be 
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metabolized by CYP3A4 and to a lesser extent by CYP2C8. In addition, troglitazone 
has shown to be a potent inducer of CYP3A4 [212, 268]. In our system troglitazone 
appears to cause a direct toxic effect as neither of the cell systems showed any 
extensive metabolism of the drug. This is supported by in vitro studies where it has 
been concluded that troglitazone induces toxicity by itself rater that the reactive 
metabolites generated [262, 269, 270]. Moreover, studies in primary hepatocytes show 
that the mitochondrial dysfunction preceded the formation of troglitazone metabolites 
[269].  
 
A immune mediated reactions has also been suggested to play a role for the toxic 
effects caused by troglitazone [271], possibly a response to the apoptotic and necrotic 
cell death seen [212]. The induced expression of the chemokines CXCL2 and CXCL10 
detected in the co-cultures indicate that there is an ongoing production of inflammatory 
mediators that may very well be able to cause infiltration of immune cells like 
neutrophils and monocytes in vivo, thereby potentiating the inflammatory response [41, 
272, 273]. When treated with troglitazone the THP-1 cells in single culture exhibited an 
increased expression of TNFα. IL-6 was induced in the THP-1 cells in both single and 
co-cultures, but predominately in single cultures. IL-1β, on the other hand, was mainly 
induced in the co-cultures. All three cytokines are known to promote an inflammatory 
response [274, 275], but TNFα and IL-6 are also known to have a hepatoprotective role 
[40, 51]. There are several studies that report that pro-inflammatory cytokines are not 
induced after troglitazone treatment [276, 277]. The overall increase in pro-
inflammatory cytokines in our study is modest but is generally more pronounced in the 
co-culture and support the viability data. Our results suggest interplay between the two 
cell types, adding to the toxic insult. Whether these mediators play a role in the 
troglitazone-induced insult or whether the observed toxicity is a combination of other 
mechanisms warrants further investigation. Further development of this co-culture 
model requires the use of metabolically competent cells and the incorporation of other 
cell types known to be important for inflammatory mediated responses, such as 
endothelial cells [60] and stellate cells [49]. In addition, a 3D culture system might 
improve long term functional maintenance of these cells. 
 
We are all constantly exposed to bacterial endotoxin, such as LPS 
(lipopolysaccharides), an important pro-inflammatory agent that can trigger the 
inflammatory innate immune response [40]. Dietary factors, such as alcohol and a high 
fat diet, significantly increase the translocation of LPS from the gut into the blood 
stream and may increase the sensitivity of the liver to toxic insults [278, 279]. Co-
administration of hepatotoxins like chlorpromazine [280] and ethanol [281] together 
with a non-hepatotoxic dose of LPS has shown to prime the Kupffer cells and 
potentiate the hepatic insult of these substances in vivo, even when given in non-toxic 
doses. A similar approach has been used in vitro where a rat co-culture model with 
Kupffer and hepatic parenchymal cells was more sensitive to hepatotoxic substances 
after LPS activation of the Kupffer cells [233]. Application of this two-hit approach 
might further improve the sensitivity of our co-culture system. 
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4.2 HEPATOCYTE-LIKE CELLS DERIVED FROM HUMAN EMBRYONIC 
STEM CELLS DIFFERNTIATED VIA DEFINITIVE ENDODERM – 
PAPERS II AND IV 
4.2.1 Directed differentiation of human embryonic stem cells in two-
dimensional culture – paper II 
The first article of hepatocyte-like cells generated from human embryonic stem cells 
(hESC) came out only a few years after the first successful generation of hESC 
cultures [282]. Since then several research groups have developed protocols for 
hepatic differentiation of hESCs, largely based on what is known about the 
developmental pathway of the liver during embryogenesis [187, 189-193, 283]. 
Unwanted spontaneous differentiation has been a major problem which has increased 
the focus on more directed and controlled differentiation of hESC with the aim to 
generate more homogenous cell populations of hepatocyte-like cells. The liver 
originates from the definitive endoderm (DE) and the induction and fate of these cells 
is regulated by a complex integrated network of gene regulators [17, 20]. In paper II, 
we applied a directed, multi-stage protocol where hESCs were differentiated towards 
hepatocyte-like cells, via DE, under conditions known to support the hepatic 
development in vivo (Figure 8). 
 
Figure 8. Schematic overview of the differentiation strategy of hESC into definitive endoderm derived 
hepatocytes. The differentiation protocol is divided into three main phases. The starting material consists 
of undifferentiated hESC cultured on mouse embryonic fibroblasts (MEF). In phase I the hESC are 
induced into definitive endoderm (DE). In phase II the DE is induced to liver progenitor cells (DE-Hep 
prog). During phase III the cells are maturated to hepatocyte-like cells (DE-Hep). Adapted from paper II. 
 
 
During embryogenesis a primitive endoderm (PrE) is also formed, giving rise to an 
extra-embryonic endoderm [284]. In the early stage of embryogenesis DE and PrE 
have a very similar differentiation pattern, despite their different faiths [285], with 
only a few known markers to discriminate between the two [286, 287]. In order to 
validate our protocol we compared the DE differentiated hESCs to intrinsic 
(spontaneous) differentiated (ID) hESCs cultured in VitroHES™ supplemented with 
FGF2. The ID protocol has previously been characterized and has been shown to 
generate hepatocyte-like cells with protein expression of GSTs [288] and mRNA 
expression of CYPs [289]. However, the ID protocol gives rise to a mixed cell 
population [289] and is considered to mainly mediate differentiation into PrE cells 
[287]. The DE cells were also compared to HepG2 cells and primary hepatocytes. 
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In the first phase of the differentiation protocol, Activin A was added to mimic 
endogenous Nodal signaling [16, 189], known to be particularly important for DE 
formation [16, 19]. A low concentration of serum (0.2%) was also added to block 
phosphatidylinositol 3-kinase (PI3K) activity since it has been shown to inhibit the 
Activin A induced differentiation of hESC [290]. Other publications have shown that 
WNT3A also contribute to an accelerated and improved hESC differentiation towards 
DE [190, 291], however, in our system Activin A in combination with FGF2 proved to 
be superior. A high yield of morphological changed DE cells was generated, 
characterized by the expression of SOX17, FOXA2 and CXCR4 [189], as compared to 
the ID cells. Only a minor part of the DE cells expressed the PrE marker SOX7 [23]. 
Additionally, the DE cells did not show the same elevated levels of early liver markers, 
like α-fetoprotein (AFP), as the intrinsic cells did which at this early stage in 
development would indicate the presence of PrE cells. 
 
In phase II, treatment with a combination of BMPs and FGFs, mimicking the 
interaction with and stimuli by mesoderm tissues observed in vivo [25, 292], changed 
the morphology of the cells into polygonal shaped cells and induced the expression of 
early hepatocyte specific genes like HNF3β, HNF4α, and cytokeratin 8 and 18 (CK8 
and CK18). Moreover, the cells showed signs of early liver development by 
significantly elevated expression of A1AT (α1-antitrypsin), AFP and FABP1 (fatty 
acid-binding protein 1), compared to the intrinsically differentiated control cells. 
Intriguingly, some cells co-expressed EpCAM (epithelial cell adhesion molecule) and 
CK19 which suggests the presence of hepatoblasts, a common progenitor to the 
hepatocytes and cholangiocyte, confirming early liver development [227]. 
 
Hepatocyte-like cells (DE-Hep) were generated in Phase III by the addition of various 
maturation factors, such as Oncostatin M (OSM) and dexamethasone (DEX), important 
for liver formation and hepatocyte maturation and function [20, 26, 27, 29]. The DE-
Hep cells had typical polygonal-shaped hepatocyte morphology with several bi-nuclear 
cells, clearly different from the cell morphology of the intrinsically differentiated cells 
(Figure 9A and 9C, respectively). Interestingly, many of the DE-Hep cells arranged 
themselves in substructures of CYP3A4/7 positive cells that have not been reported 
elsewhere (Figure 9B).  
 
Apart from the hepatocyte like morphology, the DE-Hep cells also showed 
significantly up-regulated mRNA expression of several liver related genes such as 
A1AT, albumin, AFP, HNF4α and transporters (MRP2 and OATP2), compared to the 
intrinsically differentiated control cells. Most of these genes were also detected at 
protein level. The DE-Hep possessed several hepatocyte functions, such as urea 
secretion, active indocyanine green (ICG) uptake (clearance test) and glycogen storage. 
The expression of catalytically active CYP enzymes is also an important marker for 
mature hepatocytes [111]. The mRNA expression of CYP1A2, 2C9 and 3A4 was 
significantly higher in DE-Hep cells compared to both the intrinsically differentiated 
cells and HepG2 cells. Protein expression of CYP1A2 and 3A4 was also confirmed. A 
functional drug metabolism test of the DE-Hep cultures at day 29 revealed that the DE-
Hep cells were metabolically competent for CYP1A, CYP3A and CYP2C. To-
conclude, the guided differentiation approach proved to be superior to intrinsic hESC 
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differentiation regarding hepatocyte-like morphology and hepatic protein expression. 
These data are supported by Synnergren et al. who showed major transcriptional 
differences between DE-differentiation and intrinsic differentiation when analyzed on a 
global scale [287]. However, apart from higher CYP1A2 activities observed in DE-Hep 
cells there was no significant difference in CYP activity when compared to the 
intrinsically differentiated cells. A possible reason, as suggested by a gene array 
analysis [287] could be that the intrinsic cultures may contain other CYP expressing 
cells like intestinal cells.  
 
Figure 9. Phase-contrast images of DE-Hep in phase III and intrinsically differentiated (ID) cells. A) DE-
Hep cultures at day 17. The cells exhibit a hepatocyte-like morphology and are frequently bi-nucleated. 
B) DE-Hep cultures at day 20 are starting to form multicellular structures of CYP3A4/7 positive cells 
(black arrows). C) Intrinsically differentiated control cells at day 23 (white arrows). The hepatocyte-like 
cells are located only at the periphery of the growing colony and show different morphology with no 
clear sub-structures compared to the DE-Hep cells. D) Human primary hepatocytes in culture. Adapted 
from paper II. 
 
 
4.2.2 Directed differentiation of human embryonic stem cells in three-
dimensional culture – paper IV 
 It is well known that primary hepatocytes depend on high cell density and well 
organized tissue architecture for the maintenance of their differentiated functions [218, 
219]. This is nicely illustrated by our preliminary results on primary hepatocytes 
cultured in the perfused three-dimensional (3D) bioreactors. Primary hepatocytes 
cultured in 2 ml and 0.5 ml bioreactors showed maintained CYP activities up to two 
weeks (Figure 10).  
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Figure 10. Metabolite formation after 10h incubation with four different CYP enzyme substrates 
measured at day 1 and day 11 in human primary hepatocytes cultured in a perfused bioreactor. Shown 
here is one representative experiment performed in a 0.5 ml bioreactor (Sivertsson, L., unpublished data). 
 
 
Similar results have recently been published elsewhere, using the same bioreactor 
system, showing that the hepatocytes are able to form liver-like structures in the 
bioreactors [227, 228]. Specific inter-cellular interactions and cellular organization are 
also important aspects in embryonic liver development [17, 20]. Different 3D 
bioreactor cultures, both perfused [293] and stirred [294], has successfully been used 
for hESC expansion. A study by Baharvand et al. showed that differentiation of hESC 
in collagen scaffolds resulted in improved metabolic activity compared to 2D 
differentiated cells [295]. In a recent publication, larger perfused bioreactors (8 ml) 
were successfully used for hepatic differentiation of hESC [296] and maturation of fetal 
hepatocytes [297], indicating that the 3D perfused bioreactor system may be a valuable 
tool for the differentiation of stem cells into functional hepatocytes. In order to evaluate 
if culture in the 3D bioreactor system could improve the hESC differentiation process, 
we compared cells culture in the bioreactor to cells cultured in conventional 2D culture 
as described in paper II. The undifferentiated hESC (UD) were stepwise guided through 
hepatic development, via DE and hepatic progenitors (PRO), to hepatocyte-like cells 
(HEP) as described in paper II but with some changes in the protocol (Figure 11).  
 
Originally, hESCs were cultured on top of a mouse fibroblast feeder layer and passaged 
manually twice a week to prevent spontaneous differentiation, which was both time and 
labor demanding. In addition, the use of animal cells is associated with risks such as 
pathogen and viral infections. Cellectis, Cellartis AB has recently developed a feeder-
free culture system that can be fully automated for large-scale propagation of 
embryonic stem cells, able to generate the large amount of cells needed to fill up the 2 
ml bioreactors (minimum of 25 million) for this study. Sodium butyrate and DMSO 
were included in this differentiation protocol as they both have been shown to promote 
hESC hepatic differentiation [282, 298, 299]. Moreover, DMSO has also been 
frequently used to maintain or induce differentiation of primary hepatic cells [300, 
301] as well as hepatic cell lines [175]. Fetal bovine serum (FBS) was added in phase 
II. FBS contains several important factors important for cells in culture, like growth 
factors, minerals and trace elements, transport proteins and lipids, however, the 
incubation time with serum was decreased in this protocol as it has been shown to 
negatively affect the differentiation of hESC [189] as well as the function of primary 
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hepatocytes [302]. Serum-free conditions have also been shown to result in better CYP 
activities in hESC differentiated hepatocyte-like cells [303].  
 
Figure 11. A) Schematic overview of the hepatic differentiation strategy of undifferentiated hESC 
cultured under feeder-free conditions. The differentiation protocol is divided into three main phases: 
phase I where the hESC are induced into definitive endoderm (DE), phase II where the DE is induced to 
liver progenitor cells (PRO) and phase III where the cells are maturated into liver-like cells (HEP). B) 
The cells were inoculated into the bioreactors either as definitive endoderm (DE) on day 7 or as hepatic 
progenitors (PRO) on day 12. The cells were passaged (p) and either inoculated into the 3D bioreactor or 
seeded in 2D controls. NBr: sodium butyrate. Adapted from paper IV. 
 
 
During the first 7 days of differentiation the mRNA expression of the stem cell markers 
NANOG and OCT-4 dramatically decreased and in the PRO stage they were no longer 
detectable where, in contrast, the levels of the hepatic progenitor marker AFP 
drastically increased. A global transcript array analysis of HEPs revealed significant 
differences between 2D and 3D cultured cells. In total 102 annotated genes were 
differentially up-regulated and 63 genes were down-regulated (p<0.05 and FC>2) when 
the cells were cultured in the 3D system compared to the 2D system. The functional 
properties of the differentially expressed genes were evaluated by Gene Ontology 
enrichment analysis that showed that a large fraction of the enriched annotated genes 
were related to various metabolic processes. A KEGG pathways analysis identified 10 
pathways, highly related to liver specific functions that were significantly up-regulated 
in cells differentiated in 3D. Contrary, pathways associated with apoptosis and cell 
proliferation were generally down regulated, as can usually be seen in terminally 
differentiated cells. An association analysis of the transcriptional profiles compared to 
human primary hepatocytes showed a clear pattern of stepwise hepatic maturation of 
hESC to DE, PRO and HEP (both in 2D and 3D), with the highest similarity for the 3D 
HEP cells. The expression of a large number of hepatic markers (ALB, TAT, FABP1), 
enzymes (CYP7A1, 1A2, 2C9, UGT2B7) and transporters (MRP2, OCT1) increased 
during the differentiation process were CYP7A1, CYP2C9 and CYP3A4 were 
significantly higher expressed in 3D HEP cells compared to 2D HEP cells.  
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Immunohistochemical staining of the HEP cells from the bioreactor showed that the 
cells successfully arranged themselves between the capillaries. The HEP cells stained 
positive for A1AT and CYP3A4 protein expression, suggesting a hepatocyte-like 
phenotype. The apical efflux transporter BCRP (Breast Cancer Resistance Protein) was 
also present in the bioreactor tissue. Regular analysis of metabolic parameters in the 
media circulating through the bioreactors indicated that the cells were metabolically 
active as they consumed glucose. When treated with a CYP substrate cocktail, the 
hepatocyte-like cells cultured in the bioreactor produced higher levels of paracetamol, 
hydroxybupropion and 1’-hydroxymidazolam metabolites compared to the 2D cultures, 
indicating higher CYP1A2, CYP2B6 and CYP3A4-mediated activities, respectively. 
However, the metabolic activity in the 3D differentiated HEP cells was considerably 
lower when compared to hPH.  
 
Earlier studies have shown differentiation of hESC cultures in three-dimensional (3D) 
aggregates called embryoid bodies [304, 305]. This approach proved to be inefficient 
and resulted in a mixed population of all three germ layers [16, 29]. However, it nicely 
illustrates the influence that a 3D milieu has for hESC differentiation since the 
spontaneous differentiation seen in the embryoid bodies are far more complex than the 
simple spontaneous differentiation of hESC initiated by discontinuous passaging [304, 
305]. To date, the most efficient differentiation protocols are those applying DE 
differentiation using soluble growth factors on hESC cultured in monolayers. However, 
in a static 2D culture, gas exchange only occurs via passive diffusion from the air to the 
media and media exchange is discontinuous. It has been shown that the oxygen 
concentration around the cells differs greatly comparing the in vivo with in vitro 
conditions and is mainly due to the low solubility of oxygen in cell culturing media 
[302]. The 3D bioreactor technology used here is a dynamic system with continuous 
media renewal, creating a homeostatic environment that mimics the capillary structures 
present in vivo [227]. Growth factors and nutrients are supplied and cell waste products 
are removed with low gradients. In addition, oxygen is continuously added in a low 
gradient manner, which is important since it has been shown that low oxygen supply 
affects hepatocyte metabolism [302]. 
 
The directed differentiation protocol presented here generates a high yield of 
differentiated hepatic cells that display many hepatocyte-like characteristics and 
functions. Moreover, our perfused 3D system supports and improves the directed 
hepatic differentiation and maturation of hESC. However, the generation of fully 
functional hepatocytes is still some way ahead and further research regarding the 
cellular and molecular mechanisms involved in this complex process is required. Apart 
from the media composition, other extracellular and environmental factors should be 
considered to take the differentiation process one step further. A few examples are 
incorporation of other cell types and/or the addition of extra cellular matrix (ECM) to 
the 3D cultures. In tissue, cells do not only attach to each other but also to the ECM 
which will affect how the cells respond to stimuli from their surroundings. Recently, 
Hay et al. studied the effect of ECM on hESC-derived hepatocyte-like cells and 
identified a polyurethane matrix that enhanced hESC-derived hepatocyte functionality 
and long-term growth [303].  In the future it should also be investigated whether 
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coating of the bioreactor and its fibers can improve the differentiation process of our 
cells. Paracrine signals from mesenchymal cells have also been shown to be important 
for the expansion and hepatic differentiation of human stem cells [278] as illustrated in 
vitro by a co-culture of mouse embryonic stem cells and mesoderm cells [306]. 
Differentiation of oval cells has been performed in 3D culture systems with 
mesenchymal feeder cells [307] and stellate cells [197] which facilitated their 
differentiation into mature hepatocytes.  Incorporation of hESC or DE derivates 
together with primary liver cells in the bioreactor might be another way to generate 
mature hepatocytes. This approach has previously shown to be effective for 
differentiation of mouse embryonic stem cells, co-cultured together with human non-
parenchymal liver cells [308]. Recently, interesting results have been published by a 
Japanese group which showed effective hepatic differentiation of hESC and iPSC by 
sequential transduction with various transcription factors, such as FOXA2, HNF4α and 
HNF1α [202, 309]. Notably, hepatocyte-like cells have also been generated directly 
from murine fibroblasts by transduction with the same factors, without the need for 
cellular pluripotency [310, 311]. 
 
 
4.3 HIGH CELL DENSITY-INHIBITED PROLIFERATION INDUCES 
CYP3A4 CATALYTIC ACTIVITY IN HUH7 CELLS POSSIBLY 
REGULATED BY CDK2 MEDIATED PXR ACTIVATION – PAPERS III 
AND V  
Primary hepatocytes are highly malleable, an important feature during liver injury when 
the cells exhibit a remarkable regenerating capacity via proliferation [46]. However, 
these properties constitute a problem when the cells are used for research purposes. 
When isolated from their microenvironment and placed in 2D cultures primary 
hepatocytes rapidly de-differentiate into  a population of adult liver progenitors [167], 
exhibiting an extensive loss in many mature liver function such as CYP enzyme 
activities [133, 168]. The decline was been shown to been the most rapid for CYP3A4 
[312]. One of the early mechanistic changes observed during isolation of hepatocytes is 
changed levels of transcription factors where many liver-enriched liver transcription 
factors are rapidly down-regulated [106]. The mechanism behind this phenomenon is 
not well understood but has been suggested to be caused by stress signaling induced 
during the isolation process and a loss of cellular ultrastructure [313, 314]. Primary 
hepatocytes are highly dependent on high cell density and tight cell-cell contacts, not 
only for the maintenance of their differentiated functions and organized tissue 
architecture, but also for the regulation of their proliferation [218, 219]. Previously, it 
has been shown that confluent culture of human hepatoma cell lines BC2 and B16A2 
cause the cells to re-differentiate, resulting in a gene expression pattern that is more 
similar to primary hepatocytes [315, 316]. Thus, we conducted an in-depth analysis of 
the capability of the human hepatoma cell line Huh7 to re-differentiate to more 
functional hepatic cells when grown under confluent conditions. 
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4.3.1 Confluent culture results in spontaneous differentiation and increased 
CYP3A4 catalytic activity  
The Huh7 cells were cultured confluent up to 5 weeks and compared to HepG2 cells 
cultured under the same conditions, to sub-confluent Huh7 control cells and to human 
liver tissue (HL). Growing the Huh7 cells confluent generated a dense monolayer of 
cells with a lower nuclear-to-cytoplasm ratio and the cells contained large distinct 
nucleoli, all suggestive of a more hepatocyte morphology.  A whole transcriptome 
analysis with a combined criterion of p< 0.05 and FC >2 was used to analyze statistical 
and biological differences between 4 weeks confluent and subconfluent control cells. 
Transcripts from pathways related to cell proliferation were decreased and the cells 
achieved a more hepatocyte-like phenotype with improved liver specific functions, 
such as metabolism, when grown confluent (paper V). A more in depth TaqMan gene 
expression analysis revealed that confluent culture of Huh7 cells up to 5 weeks 
resulted in a gradual increase in mRNA expression levels for several CYPs, UGTs, 
transporters, transcription factors and other liver specific genes (paper III). The 
largest effect was observed for CYP3A4 with a substantial increase in mRNA and 
protein expression after 4 weeks of confluent culture, to levels comparable to that 
seen in human liver. However, no effect was observed on the expression levels of the 
other CYP3A isoforms. The increase in CYP3A4 mRNA and protein expression was 
accompanied by a time-dependent increase in catalytic activity that correlated well 
with the protein levels, determined to be approximately 30% of the activity in HL 
microsomes (paper III). The increase in CYP3A4 activity was also accompanied by 
increased protein levels of the electron donors NADPH cytochrome P450 reductase 
(POR) and cytochrome b5. In addition, POR enzyme activity was increased to 
approximately 50% of that observed in HL. The 4 week confluent Huh7 cells were 
also able to metabolize testosterone and midazolam, confirming the previous activity 
result. Since the confluent cells were metabolically active, they were also able to 
respond to CYP3A4-mediated aflatoxin B1 cytotoxicity. Moreover, the toxic effect 
was effectively prevented by the CYP3A4 inhibitor ketoconazole (paper III). These 
results show that high cell density and tight cell-cell contacts are indeed important for 
the functionality of the Huh7 cells, much like the situation in the liver in vivo. The 
importance of cell density and cell-cell contacts was further underscored when the 
CYP3A4 competent confluent cells were trypsinated and replated subconfluent, and the 
CYP3A4 levels rapidly dropped back to those observed in the subconfluent control 
cells (paper V). This resembles the in vivo situation where CYP3A4 expression 
drastically decreases during liver regeneration [317]. The Huh7 cells were able to 
maintain CYP3A4 activities in long-time culture, albeit at lower levels. After 8 weeks 
of confluence the activity levels were comparable to the levels seen in 3 weeks 
confluent cells. 
 
4.3.2 Cell line specific differentiation during confluent culture 
It is clear that the phenotypical change occurring during confluent growth is cell line 
specific and does not apply to all hepatic cell lines, as illustrated by our results on 
HepG2 cells. Very little effect was seen in HepG2 cells cultured under the same 
conditions as the Huh7 cells, with no effect on any of the CYP genes investigated 
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(paper III). The reason behind the inability of HepG2 to re-differentiate is not known, 
but probably is related to the proliferation status of HepG2 cells which seems to not be 
contact inhibited, contrary to the Huh7 cells. Confluent growth of the B16A2 
hepatoma cell line also resulted in an increase in metabolic pathways and liver 
specific genes, however, these cells did not express the same levels of metabolically 
competent genes as the Huh7 cells. In B16A2 cells only a moderate effect was seen 
for CYP3A4 (about 8-fold increase) compared to the massive effect in the Huh7 cells 
and might be caused by the lack of PXR and CAR expression in B16A2 cells [316]. 
Contrary, the B16A2 cells showed increased expression in CYP2E1 (about 7-fold) 
[316] which was unaffected in the Huh7 cells.  
 
4.3.3 Transcriptional regulation of CYP3A4 
In order to investigate if the increased CYP3A4 gene expression in the confluent Huh7 
cells was indeed transcriptionally regulated, several reporter constructs containing the 
three well-known CYP3A4 5’-flanking regulatory regions, PROX, XREM and 
CLEM4, were created. The activities of all the different constructs were significantly 
higher in confluent cells compared to control cells and the largest activity was observed 
with the CYP3A4-PXC-luc construct (Figure 7, paper V), indicating that all three 
regions are important for CYP3A4 regulation in these cells. The transcriptional activity 
of the CYP3A4-PXC-luc was increased in a time-dependent manner during confluency 
and correlated well with the observed increases in CYP3A4 mRNA, protein and 
catalytic activity (paper V). Next the regulatory mechanisms underlying the CYP3A4 
specific up-regulation were investigated. In confluent Huh7 cells, the mRNA 
expression levels of many of the hepatic transcription factors analyzed where similar to 
the levels observed in HL (paper III). The expression of CYP3A4 is known to be 
regulated by many different transcription factors with PXR considered to be the most 
important modulator [126-128]. Due to the low expression of PXR in many cell lines, 
most studies regarding PXR regulation have relied on transient transfection of PXR 
together with responsive reporter plasmids and often with the addition of inducers, such 
as rifampicin. In the Huh7 cells PXR mRNA and protein expression was increased 
during confluence and, moreover, PXR protein accumulated in the nuclei (paper V). 
This effect was endogenous and did not require any addition of inducers. Apart from 
the increased CYP3A4 expression, other PXR regulated CYPs, like CYP2B6 or 
CYP2C9 [145, 318], were also induced in the confluent cells. Furthermore, the 
addition of the PXR dependent CYP3A4 inducer rifampicin [158] significantly 
induced the CYP3A4 promoter activity as well as the CYP3A4 metabolic capacity in 
the confluent cells, confirming a regulatory role of PXR in our confluent cells. 
Contrary, rifampicin was unable to induce CYP3A4 expression in the subconfluent 
control cells, indicating that PXR is not transcriptionally competent in those cells. We 
could also conclude that endogenous RXR levels were also not a limiting factor in 
control cells (paper V). The CYP3A4 activity in the confluent cells was effectively 
inhibited by ketoconazole (paper III). PXR knock-down in confluent cells significantly 
reduced the PXR mRNA expression by 60% along with a 40% reduction of CYP3A4 
mRNA expression compared to cells transfected with nontargeting siRNAs, further 
confirming the transcriptional role of PXR. Notably, when the confluent cells were 
trypsinated and replated subconfluent, the PXR protein levels rapidly dropped to levels 
Louise Sivertsson 
38 
comparable to those observed in control cells (paper V). Thus, the effect of confluence 
on the PXR levels is reversible and follows the CYP3A4 expression data. Together 
these results indicate that the observed increase in CYP3A4 mRNA, protein and 
activity levels is, at least partly, mediated through transcriptional activation via the 
PXR receptor.  
 
4.3.4 Cell division and PXR regulation 
PXR is dynamically regulated by its phosphorylation status which in turn affects its 
expression levels, ligand and DNA binding, localization, interaction with other 
modulators and protein stability [319]. Several studies have demonstrated a role of 
phosphorylation-dependent signaling events in the regulation of PXR-mediated CYP 
gene expression [138, 139, 160] and several putative serine and threonine 
phosphorylation sites have been identified within the human PXR protein [138]. It has 
been shown that CDK2 (cyclin-dependent kinase 2) is able to inhibit PXR activity by 
directly phosphorylating the receptor at Ser350 [320]. Active CDK2 inhibits the 
interaction of human PXR with SRC-1 via phosphorylation of PXR which attenuates 
PXR-mediated CYP3A4 gene expression [318, 320]. These findings were supported by 
another study in HepG2 cells, showing that the use of an antimitogenic factor inhibiting 
CDK2 or CDK2 knock-down resulted in increased levels of CYP3A4 [321]. CDK2 is a 
well-known key regulator of cell cycle progression. During liver regeneration, CDK2 
is activated by CDK-activating kinase (CAK) and by association with the regulatory 
units cyclin E/A [318, 322]. The negative regulation of CDK2 has been shown to 
involve PP2Cs (protein phosphatase type 2C), which dephosphorylates and inactivate 
CDK2. As a result, cell cycle is arrested and the inhibitory effect of CDK2 is 
abolished, enhancing the hPXR-mediated CYP3A4 promoter activity [318, 322]. We 
addressed whether CDK2 was involved in the regulation of CYP3A4 expression in the 
proliferation-inhibited confluent cells. Indeed, we found that the CDK2 protein 
expression was significantly higher in subconfluent control cells compared to confluent 
cells. Knocking-down CDK2 in proliferating control cells resulted in increased PXR 
and CYP3A4 protein levels. Moreover, when the confluent cells were trypsinated and 
replated at low density the cells started proliferating again, resulting in increased CDK2 
levels and, as a consequence, decreased the PXR and CYP3A4 levels (paper V). Our 
results presented here are consistent with the in vivo concept where both the activity of 
hPXR and the expression of CYP3A4 are regulated in a cell cycle- and cell 
proliferation-dependent manner (Figure 12) [317, 318]. 
  
4.3.5 DMSO effect on cell differentiation 
DMSO is a common solvent used in drug metabolism and toxicity studies but is also 
used extensively to induce and maintain hepatic functions of primary cells [300, 301], 
oval cells [323], stem cells [299] and cell lines [175]. Moreover, DMSO has been used 
to induce hepatic functions in Huh7 cells where culture in 1% DMSO stops the 
proliferation and generate cells with more hepatocyte-like phenotypes and induced 
expression of several liver specific genes and phase I and II enzymes [324]. Choi et al. 
also describe a drastic effect on CYP3A4 expression when culturing the cells in DMSO 
for several weeks [324], comparable to our results in the confluent cells. However, we 
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could demonstrate that growing Huh7 cells confluent for 4 weeks in the presence of 
1% DMSO did not have any additional effect on CYP3A4 protein and activity levels 
as compared with 4-week confluent cells cultured without DMSO (paper III). In the 
data presented by Choi et al., DMSO treatment resulted in increased levels of CAR 
whereas PXR was unaffected, moreover, neither of the two transcription factors was 
inducible [324]. This suggests major differences in the regulatory mechanism behind 
the CYP3A4 induction in these two cell systems. In addition, it has been shown that 
DMSO inhibits several P450s, as well as CYP3A4, in a substrate-dependent way and 
would therefore not provide inaccurate assessment of drug interaction potentials [325, 
326]. 
Figure 12. Proposed mechanism for the involvement of CDK2 in the PXR dependent regulation of 
CYP3A4 in Huh7 cells. In the non-confluent proliferating Huh7 cells the levels of active CDK2 are 
increased, which results in increased levels of phosphorylated PXR. Phosphorylation of PXR affects 
ligand binding and cytosol-nucleus translocation. Phosphorylation may also target PXR to be degraded 
and, subsequently, the transcriptional activation of CYP3A4 is reduced. In the confluent cells, cellular 
proliferation is inhibited and cell cycle is arrested, resulting in decreased levels of active CDK2. 
Unphosphorylated PXR can now be activated, possibly by an endogenous ligand or by other processes, 
heterodimerize with RXR and be translocated into the nucleus. Here it can bind, together with cofactors, 
to the regulatory elements of the CYP3A4 gene, resulting in increased expression of CYP3A4. Figure 
from paper V. 
 
 
The mechanism by which DMSO induces differentiation of certain cell types still 
remains obscure but DMSO has been shown to increase the levels of PKC [327], to 
inhibit histone deacetylases [328] and to increase the levels of cadherin and integrin 
complexes [329], all contributing to inhibited proliferation and increased gene 
transcription. Our hypothesis behind the altered differentiation status in our cells relies 
on a similar mechanism, but is induced by the formation of endogenous cell-cell 
contacts rather than by chemicals. Cell-cell contacts via adherens junctions (E-
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cadherin/β-catenin) are essential for terminal differentiation of hepatocytes [330]. 
Immunocytochemical staining of confluent Huh7 cells indicate that the cells formed 
both tight junctions (coxsackie virus and adenovirus receptor staining, CXADR) and 
adherens junctions (β-catenin staining), both important for proper hepatocyte 
polarization and function (Figure 13).  
 
Figure 13. Immunocytochemical staining with CXADR (coxsackie virus and adenovirus receptor) and β-
catenin, representative of tight junctions and adherens junction formation respectively (Sivertsson, L., 
unpublished data). 
 
 
In the subconfluent control cells, only the places were the cells touch each other have 
positive CXADR staining whereas in the confluent cells homogenous tight junctions 
have been formed between the cells. The highly intense CXADR staining on certain 
locations between the confluent cells may be indicative of bile canalicular structures. 
Positive β-catenin staining is seen in the confluent cells, indicative of the formation of 
adherens junctions. The control cells, which have just reached confluence, also stain 
positive for β-catenin although with a more diffuse staining pattern (Figure 14). These 
results are in good agreement with the array results and support cell-cell contact 
inhibited proliferation in the confluent cells. 
 
In summary, as the Huh7 cells grow confluent proliferation is inhibited and the cells 
undergo a spontaneous differentiation without the addition of inducers. CYP3A4 is 
clinically the most important CYP enzyme, estimated to be involved in the metabolism 
of about 50% of the marketed drugs [111]. Better understanding of the regulation of 
CYP3A4 and the encoded enzyme is therefore of major clinical significance. Moreover, 
drugs interacting with PXR are considered likely to be involved in drug-drug 
interactions. It is well accepted that PXR regulation exhibits a species-specific profile 
which makes the confluent Huh7 cells a valuable system to assess human PXR 
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activation as well as drug-drug interactions involving PXR and CYP3A4. Moreover, 
contrary to transient transfection models, involving plasmid based PXR and CYP3A4 
promoter constructs, the actual effect on the metabolic CYP3A4 activity can be 
assessed. The high constitutive expression of CYP3A4 also makes the confluent Huh7 
cell system useful to study mechanisms behind PXR and CYP3A4 gene regulation and 
might contribute to a better understanding of the large inter-individual differences in 
hepatic CYP3A4 expression. 
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5 CONCLUSION 
This thesis can be concluded as follows: 
 
 
• Treatment of a human in vitro co-culture cell model, consisting of hepatocytes 
and monocytes, with the hepatotoxic drug troglitazone results in a potentiated 
and more rapid cytotoxic response compared to single cell cultures. 
Troglitazone treatment also causes increased expression of several 
inflammatory and stress-related genes in both cell types during co-culture. In 
contrast, the non-hepatotoxic drug rosiglitazone does not cause any significantly 
effect in either cell systems. 
 
• Our controlled, stepwise differentiation protocol guides the human embryonic 
stem cells, via definitive endoderm and progenitor stages, to hepatocyte-like 
cells. Gene and protein expression as well as functional data, indicate that the 
hepatocyte-like cells exhibit many hepatocyte-specific features and functions, 
including CYP metabolic activities. 
 
• The hepatic gene and protein expression and functionality of the differentiated 
hepatocyte-like cells are further improved by three-dimensional culture in the 
bioreactor system compared to the standard two-dimensional culture. 
 
• Confluent culture of the human hepatoma cell line Huh7 induces a spontaneous 
hepatic differentiation process without the need for the addition of inducers. A 
major effect is observed for CYP3A4 gene and protein expression as well as 
catalytic activity. 
 
• The large increase in CYP3A4 expression in the confluent Huh7 cells is 
mediated by increased PXR transcriptional activity, possibly as a result of 
decreased CDK2 activity and cell cycle arrest.  
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6 GENERAL SUMMARY AND FUTURE PERSPECTIVES 
Drug induced liver injury (DILI) is a significant problem in drug discovery, much 
owing to the shortcomings of pre-clinical model systems which often fail in the 
extrapolation to human biology. The underlying mechanism by which DILI develops 
is complex and involves multicellular interactions [13]. Toxins affect not only the 
hepatocytes but also other cells, at concentrations that may not be toxic for the 
hepatocytes. Therefore, in vitro cell models ideally should include biotransformation-
competent hepatocytes as well as other hepatic cell types, in order to accurately predict 
in vivo toxicity. A more in vivo-like milieu in 3D cultures with different cell types has 
shown to be crucial for the maintenance of hepatocyte specific functions [229, 231], as 
well as for the facilitation of hepatic maturation of stem cells [20, 197, 307]. Apart 
from the hollow fiber bioreactor described in this thesis [227, 228], several promising 
3D spheroid systems have recently been developed. Stir-tank reactors where hepatocyte 
spheroids are cultured under stirred, perfused, controlled conditions have shown 
maintained gene expression of phase I and phase II enzymes as well as hepatic 
functions, such as albumin and urea synthesis, up to two weeks [224]. InSphero 
(www.inspero.com) has developed human liver microtissue spheroids, which display 
long-term maintained liver functions, like albumin secretion and CYP activities. These 
spheroids contain both hepatocytes and non-parenchymal cells, including Kupffer cells, 
and have shown increased sensitivity to inflammation-mediated drug toxicity 
(InSphero). Interestingly, liver-like structures, e.g. bile canaliculi, are formed in the 
hollow fiber bioreactors [227, 228] and also in the spheroid systems [224]. Hence, these 
systems might be an important tool for the identification and characterization of drug 
induced pathological changes, like indications of cholestasis, necrosis and steatosis. 
 
It has become evident that both metabolic as well as immune related factors are 
important for both type I and type II ADRs caused by many drugs [13]. To be able to 
predict immune-mediated drug toxicity, multi-cellular hepatic in vitro systems 
containing a population of immune competent cells could be of great importance 
[233]. Moreover, mixed-cellular systems could also be valuable “two-hit models”, 
where the hepatotoxic effects of drugs in combination with a sensitized liver state, such 
as steatosis and/or inflammatory stimuli like LPS, could be evaluated [331, 332]. 
Ideally, combined pairs of drugs with the same pharmacological target but different 
toxic potential (i.e. troglitazone/rosiglitazone) should be used to validate these in vitro 
systems. In addition, these systems might also assist in the search for more accurate 
and sensitive DILI biomarkers [13]. 
  
The unique characteristics of stem cells make them an attractive large-scale source of 
hepatic cells for drug development and safety assessment. Stem cells also have the 
potential to revolutionize the medical care regarding therapeutic applications. Liver 
transplantation treatments are often hampered due to shortage of donor organs and are 
also connected with high risks and lifelong immunosuppressive therapy for the patient 
[333]. As a complement, hepatocyte transplantation has successfully been applied in 
the clinic for bridging patients until liver recovery and also for treatment of patients 
with metabolic disorders [334, 335]. However, the shortage of high quality livers for 
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cell isolation highlights the need for hESC derived hepatocytes. Furthermore, the recent 
advances in human iPSC research might open up for individual-specific research and 
therapy by the creation of patient- and disease-specific stem cells [178]. By generating 
different cell types originating from the same patient and combining these into 
integrated artificial liver systems, the mechanistic differences between DILI sensitive 
and DILI insensitive patients may be studied. Moreover, the use of iPSC minimizes the 
risk of immune rejections as they are derived from the same individual. Moreover, 
these cells are not associated to the same ethical issues as hESC.  
 
Even though good progress has been made in the last 15 years, the in vitro 
differentiation of hESC into linage-restricted functional cells has proven to be a 
challenging task. The use of stem cells for the generation of hepatocytes has yet to 
overcome several obstacles, like low metabolic functions, in order to fulfill the 
requirement as a powerful tool for drug development and safety assessment. The 
molecular program that initiates and sustains human liver development still remains 
elusive and we have to increase our understanding of the coordinated developmental 
cues/signals these cells receive in vivo. Furthermore, during liver development, 
hepatocytes mature in a 3D environment with a number of other cell types that are 
important for their differentiation. While the 3D hollow fiber bioreactors enable a 
more in vivo like environment, the technique has to be further developed and the 
incorporation of ECM and other cell types has to be evaluated. By combining several 
bioreactors in the same perfusion circuit it is possible to include bioreactors of hESC 
together with reactors containing other cell types, such as mesodermal cells or primary 
cells, so that the impact of soluble factors released by these cells can be evaluated. A 
similar set up could be applied for primary hepatocytes and immune cells with the aim 
to provide an immune sensitized system with long term metabolically competent 
hepatocytes for DILI studies. 
 
By combining our knowledge regarding mechanisms and signaling pathways involved 
in liver regeneration, de-differentiation of isolated hepatocytes, maturation of semi-
specialized cells like oval cells and hepatoblasts and hESC differentiation, we should 
get a better insight into the mechanisms behind hepatic cell specialization and how to 
prevent the loss of it. Moreover, the re-differentiation process of hepatoma cells, like 
the Huh7 cells, might also provide important clues as cancer cells and stem cells share 
many common features and high similarities in their overall gene expression patterns, 
miRNA expression and epigenetic status [336]. Several genes that frequently are up-
regulated in tumors, such as c-myc [337], KLF4 [338] and β-catenin [17, 339], are 
also known to contribute to the hESC phenotype. Many of these genes also constitute 
the foundation of the successful generation of iPSC [178]. 
 
To conclude, in order to reduce the prevalence of ADRs and late stage drug discovery 
failures, more sophisticated human in vitro models have to be developed where cells 
are cultured under more physiological relevant conditions. At the same time, more 
effective and accurate in vitro screening methods of new drug candidates may also 
reduce the use of laboratory animals. 
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